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1. INTRODUCTION 
Valproate, also known as valproic acid (VPA), is one of the most frequently 
prescribed antiepileptic drugs (AEDs) (Perucca, 2002), with more than one 
million people around the world estimated to be taking VPA every day 
(Farinelli et al., 2015). VPA was first synthesized in 1882 by Beverly S. Burton 
as an analogue of valeric acid, which is naturally produced by Valeriana offi-
cinalis (Burton, 1882) (Figure 1). VPA is a simple-branched short-chain fatty 
acid that is a clear liquid at room temperature (Figure 2). Initially, VPA was 
used as a solvent for organic compounds. There was no known clinical use of 
this drug until its anticonvulsant activity was serendipitously discovered by 
Pierre Eymard in 1962 (Chateauvieux et al., 2010).  
After being approved as an anticonvulsant in France in 1967, VPA was 
marketed in more than 100 countries for the treatment of epilepsy (Levy, 2002). 
Since then, more than 10 new AEDs have been discovered and marketed around 
the globe. Despite this fact, VPA remains a first-choice agent for most idio-
pathic and symptomatic generalized epilepsies (Perucca, 2002). In recent years, 
VPA has been successfully used for other indications, including bipolar dis-
order, migraine headache, and pain related to diabetic neuropathy (Bril et al., 
2011; Nanau and Neuman, 2013). VPA has been used in the treatment of various 
cancers (Weller et al., 2011) and has shown possible neuroprotective potential 
in patients with Alzheimer disease (Zhang et al., 2010). These chronic con-
ditions usually require long-term treatment, which emphasizes the importance 
of the long-term safety of the drug.  
VPA has a broad range of side effects, leading to its frequent designation as 
a “dirty drug” (Panayiotopoulos, 2010). Frequently reported adverse effects 
include postural tremor, hyperammonemia, alopecia, liver toxicity, and gastro-
intestinal and hematological effects (Perucca, 2002). VPA influences embryo-
genesis, causing an increased rate of major congenital malformations and 
behavioral anomalies among children exposed to the drug in utero (Tomson and 
Battino, 2012). These effects could be due to VPA’s role as a potent promotor 
of histone acetylation and its ability to influence gene transcription directly 
(Chateauvieux et al., 2010). The most common side effect of VPA treatment is a 
weight gain, which occurs in about half of patients, and is associated with 
important metabolic and endocrine abnormalities (Verrotti et al., 2009). 
Metabolic syndrome (MS) refers to a cluster of metabolic risk factors, such 
as glucose intolerance, dyslipidemia, central obesity, and hypertension, which 
are major risk factors for cardiovascular and cerebrovascular diseases (Reaven, 
1988). MS is a major economic burden and public health problem (Fu et al., 
2007; Wang et al., 2010). In people with epilepsy, a sedentary lifestyle and 
AED use contribute to obesity and MS (Ben-Menachem, 2007; Steinhoff et al., 
1996). Numerous studies have explored the effects of different AEDs on 
specific metabolic and anthropometric parameters, such as the plasma lipid 
concentration and occurrence of obesity. However, few studies have examined 
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the presence of MS in patients with epilepsy. Verrotti et al. showed that the 
presence of MS in VPA-treated children and adolescents who became obese did 
not differ from MS prevalence in otherwise healthy overweight subjects (Verrotti 
et al., 2010). On the other hand, Kim and Lee reported that women with epilepsy 
on VPA monotherapy more frequently suffered from MS compared to women 
treated with carbamazepine (CBZ), lamotrigine (LTG), or topiramate (TPM) 
(Kim and Lee, 2007).  
No study to date has explored the risk of MS in VPA-treated patients at the 
population level. Thus, the aim of this study was to evaluate the prevalence of 
MS and possible relevant factors for MS development in VPA-treated patients 
with epilepsy in Estonia, compared to the general population and to CBZ-treated 
patients, as well as to explore possible molecular mechanisms of metabolic chan-








Figure 2. Structure of valproic, valeric and γ-aminobutyric acid 
14 
2. LITERATURE REVIEW 
2.1. Use of valproic acid in treatment of epilepsy 
Despite extensive research, the precise mechanism underlying the anticon-
vulsive activity of VPA is not fully understood (Perucca, 2002). VPA increases 
activity of gamma amino butyrate (GABA) through increased synthesis, 
decreased turnover, and reduced degradation, thereby potentiating GABAergic 
transmission in specific brain regions (Chateauvieux et al., 2010). VPA 
attenuates N-methyl-D-aspartate-mediated excitation (Zeise et al., 1991) and 
participates in blockade of voltage-dependent sodium channels (McLean and 
Macdonald, 1986). There is some evidence that VPA could modulate dopa-
minergic and serotoninergic transmission (Loscher, 1999). Thus, the anti-
convulsive property of VPA is probably backed by multiple complex modes of 
action.  
VPA is extensively (≥90%) bound to plasma proteins, mainly albumin, and 
metabolized in the liver. There are at least three routes of VPA metabolism in 
humans. Microsomal glucuronide conjugation and β-oxidation in mitochondria 
are major routes, accounting for metabolism of 50% and 40% of the VPA dose, 
respectively. As a minor route, cytochrome P450-dependent oxidation accounts 
for ~10% of dose metabolism (Ghodke-Puranik et al., 2013). VPA has the 
widest spectrum of use among AEDs, being effective against all seizure types at 
efficacies comparable to those of alternative AEDs. At the start of treatment, 
especially when the precise epileptic syndrome is unclear, VPA may be started 
in all cases. Tolerability issues and adverse effects determine whether an 
alternative AED would be preferred in an individual patient (Perucca, 2002). 
VPA is especially effective against absence seizures and juvenile myoclonic 
epilepsy (Glauser et al., 2013). Intravenous (IV) infusion of VPA at doses of 
15–45 mg/kg is widely used in the treatment of established status epilepticus. 
Safety studies of IV VPA in patients with status epilepticus showed a low 
overall incidence (<10%) of adverse events, which mainly encompassed 
dizziness, mild hypotension, and thrombocytopenia (Trinka et al., 2014). Thus, 
VPA represents a safe and effective alternative to phenobarbital and phenytoin 
in the treatment of status epilepticus (Trinka et al., 2015).  
 
 
2.2. Use of valproic acid for other indications 
VPA is a first-line drug for the treatment of bipolar disorder (Johannessen and 
Johannessen, 2003) and is efficacious for treating acute episodes of mania 
(Macritchie et al., 2003). VPA is used in the acute treatment of severe migraine 
attacks (Mulleners et al., 2015; Shahien et al., 2011; Sheridan et al., 2015). In 
the prophylactic treatment of migraine, VPA was found to reduce the mean 
monthly headache frequency by ~4 days (Mulleners et al., 2015). Evidence-based 
guidelines of the European Federation of Neurological Societies / European 
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Academy of Neurology suggest that VPA be used as a first-choice drug for 
migraine prophylaxis (Evers et al., 2009). VPA has been approved for the 
treatment of trigeminal neuralgia (Ross, 2000). According to guidelines of the 
American Academy of Neurology, VPA may be effective for the treatment of 
diabetic polyneuropathy (Bril et al., 2011).  
A relatively new clinical application area of VPA is the treatment of leu-
kemia and some solid tumors (Chen et al., 2012). In a recent retrospective study 
of survival among patients with glioblastoma, subjects who received VPA con-
comitantly with temozolomide had longer survival times compared to subjects 
who received temozolomide monotherapy. The precise mechanism of this 
phenomenon is unclear; however, the antitumor effect of VPA could be 
mediated through increased bioavailability of temozolomide or inhibition of 
histone deacetylation (HDAC), as the latter effect probably potentiates the 
benefit from radiochemotherapy (Weller et al., 2011). For brain-tumor patients 
with epilepsy, the preferred treatment is a non-enzyme-inducing AED (Perucca, 
2013). Although there are no prospective randomized trials to determine which 
AED provides the best risk-benefit ratio in individual patients, VPA as a first-
line non-enzyme-inducing anticonvulsant could have the advantage. Promising 
results have been obtained in preclinical studies assessing the potential of VPA 
in the treatment of Duchenne muscular dystrophy, HIV infection, and Parkinson, 
Huntington, and Alzheimer diseases. However, there is insufficient evidence to 
determine whether VPA could be used in the clinical practice for any of these 
indications (Chateauvieux et al., 2010).  
 
 
2.3. Adverse effects of valproic acid 
2.3.1. Gastrointestinal effects 
Gastrointestinal side effects, such as nausea, vomiting, and gastrointestinal 
distress, occur in up to 25% of patients who take VPA (Dreifuss et al., 1987). 
Diarrhea, abdominal cramps, and constipation are more rarely observed at the 
start of treatment (Wagner et al., 2000). Manifestations of gastric intolerance are 
less pronounced when the drug is an enteric-coated formulation or administered 
with food (Perucca, 2002). 
 
 
2.3.2. Hair loss 
Hair loss, hair thinning, or regrowth of curly or differently colored hair may 
occur with VPA use (Johannessen and Johannessen, 2003). Alopecia due to telo-
gen shedding may appear within 3 months of treatment initiation (Chateauvieux 
et al., 2010). This effect is usually reversible and may remit even when 




2.3.3. Hematological disorders 
VPA can affect pro- and anti-coagulatory factors, leading to thrombocytopenia, 
impaired platelet function, reduced serum fibrinogen and von Willenbrand 
factor antigen levels (Zeller et al., 1999), and factor XIII deficiency (Pohlmann-
Eden et al., 2003). Some reports found that VPA increases the risk of post-
surgical bleeding (Pohlmann-Eden et al., 2003; Tetzlaff, 1991), leading authors 
to recommend that VPA be discontinued before surgery (Anderson et al., 2003). 
However, the increased risk of postoperative bleeding in patients undergoing 
neurosurgery was not confirmed in clinical trials (Anderson et al., 1997; Psaras 
et al., 2008; Ward et al., 1996). A recent study by Zighetti et al. monitored 
primary hemostasis in VPA-treated patients with epilepsy and healthy controls. 
Those authors found no significant differences in coagulation or primary hemo-
stasis (Zighetti et al., 2015). Nevertheless, some neurosurgeons are still reluctant 
to operate on patients who are using VPA. In this case, an appropriate alternative 
could be levetiracetam, which has a low interaction potential, good tolerability, 




There have been frequent reports of hyperammonemia among patients on VPA 
therapy (Murphy and Marquardt, 1982; Zaccara et al., 1987). The hyperammo-
nemia is typically asymptomatic and detected only by blood tests, although 
symptoms of encephalopathy, confusion, vomiting, and ataxia have been noted 
occasionally (Davis et al., 1994). The mechanism of hyperammonemia is 
related to the accumulation of toxic levels of VPA metabolites subsequent to the 
reduction of levels of hepatic N-acetylglutamate, which catalyzes the first step 
in urea biosynthesis (Deutsch et al., 2009). High concentrations of ammonia in 
the brain cause elevated levels of glutamine within astrocytes, resulting in 
astrocyte swelling, cerebral edema, and metabolic consequences (Brusilow, 
2002). Polytherapy may exacerbate hyperammonemia (Johannessen and Johan-
nessen, 2003). VPA may decrease plasma carnitine levels, thereby enhancing 
hyperammonemia (Nanau and Neuman, 2013). VPA can form an ester with 
carnitine, and this ester has a high renal clearance rate. Carnitine deficiency 
inhibits the urea cycle secondary to a lack of precursor molecules and adenosine 
triphosphate (LaBuzetta et al., 2010). Levocarnitine supplementation is recom-
mended for VPA-induced liver toxicity, hyperammonemic encephalopathy, and 
VPA overdose (Perucca, 2002).  
 
 
2.3.5. Hepatotoxicity and pancreatitis 
Transient elevations of hepatic enzymes without clinical symptoms are seen in 
15–30% of VPA-treated patients (Anderson, 2002). The overall prevalence of 
severe liver toxicity is about 1:20,000 among VPA-treated patients, but may be 
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as high as 1:600 or 1:800 among infants under 2 years of age, with incidence 
decreasing with increasing age (Perucca, 2002). For this reason, VPA use is 
contraindicated in this population (Nanau and Neuman, 2013). Factors that 
increase the risk of liver toxicity are polytherapy, especially in children with 
mental retardation, coexistence of certain metabolic defects (β-oxidation 
disorders, mitochondrial diseases), pre-existing liver disease, and elevated liver 
enzyme levels (Bryant and Dreifuss, 1996; Dreifuss et al., 1989; Konig et al., 
1994). In recent years, there has been a remarkable decrease in the incidence of 
VPA-associated hepatic injury. This drop may be related to better recognition of 
hepatic injury-related symptoms by physicians, avoidance of VPA in high-risk 
groups, and rapid discontinuation of VPA after early diagnosis of hepatic injury 
(Konig et al., 1994).  
Long-term VPA treatment is associated with nonalcoholic fatty liver disease 
(NAFLD), a group of diseases characterized by hepatic steatosis and hepatic fat 
accumulation without an underlying secondary cause (Farinelli et al., 2015). 
Prevalence of NAFLD in the general population is about 20–25% (Chalasani et 
al., 2012; Loria et al., 2010). NAFLD has two subsets: nonalcoholic fatty liver 
and nonalcoholic steatohepatitis. Nonalcoholic fatty liver is characterized by the 
presence of intrahepatic fat accumulation without evidence of hepatic injury. On 
the other hand, nonalcoholic steatohepatitis is associated with inflammation and 
hepatic injury, and poses a risk for development of cirrhosis and hepatic 
malignancy (Farinelli et al., 2015). Luef et al. observed ultrasound features of 
fatty liver disease in 61% of epilepsy patients treated with VPA monotherapy 
for at least 2 years, compared to 23% of patients treated with CBZ (Luef et al., 
2004). The pathogenic mechanism of VPA-induced NAFLD is not fully 
understood, but it is likely a consequence of VPA-induced weight gain and MS 
(Farinelli et al., 2015). The flux of fatty acids to the liver through the portal vein 
causes hepatic lipogenesis (Fishbein et al., 2006). In a study by Verrotti et al., 
ultrasound-diagnosed NAFLD was found more frequently among VPA-treated 
patients compared to normal-weight controls, but was found at similar rates 
among VPA-treated patients and weight-matched controls. This finding 
suggests that the development of NAFLD is not a consequence of the direct 
action of VPA metabolites, but rather the result of weight gain and MS (Verrotti 
et al., 2011a). VPA-associated pancreatitis is a relatively rare condition. Features 
of this adverse effect include elevated serum amylase and/or lipase levels and 
epigastric abdominal pain. After discontinuation of VPA, symptoms usually 
disappear (Nanau and Neuman, 2013). 
 
 
2.3.6. Mitochondrial toxicity 
As a simple fatty acid, VPA is a substrate for the fatty acid β-oxidation pathway 
in mitochondria. Thus, VPA toxicity could be related to its interference with 
mitochondrial β-oxidation (Silva et al., 2008). Among the AEDs, VPA has the 
highest potential to induce mitochondrial toxicity. VPA treatment could be fatal 
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for patients with some mitochondrial diseases, such as inborn errors of metabo-
lism that affect β-oxidation (Finsterer and Zarrouk Mahjoub, 2012). Certain 
mitochondrial disorders are associated with epilepsy and sometimes are treated 
with VPA. However, VPA treatment is contraindicated for patients with the 
mitochondrial diseases, including MELAS (mitochondrial myopathy, ence-
phalopathy, lactic acidosis and stroke syndrome); MEMSA (myoclonic epi-
lepsy, myopathy, and sensory ataxia); MERRF (myoclonic epilepsy with ragged 
red fibers); Leigh syndrome; and Alpers-Huttenlocher syndrome (Finsterer and 
Segall, 2010). This contraindication is particularly important in patients with 
catalytic deficiency in the mitochondrial DNA polymerase γ (POLG) activity, 
caused by mutation of nuclear gene POLG1 (Nanau and Neuman, 2013). POLG 
is the only DNA polymerase found in mitochondria, and its deficiency results in 
refractory seizures, progressive neuronal degeneration, and liver disease (Palin 
et al., 2010).  
 
 
2.3.7. Neurological side effects 
Central nervous system adverse effects of VPA treatment, such as sedation and 
cognitive dysfunction, are observed but not prominent and may result from 
interactions with concomitantly given AEDs. The most common neurological 
adverse effect is postural tremor, a dose-related side effect that resembles 
essential tremor (Perucca, 2002). Less-frequent central nervous system adverse 
effects of VPA include dizziness, mood changes, extrapyramidal symptoms, 
nystagmus, and headache (Chateauvieux et al., 2010). VPA treatment is occa-
sionally related to encephalopathy, which may involve development of a con-
fused state, stupor, or coma, and is fully reversible after VPA discontinuation. 
This condition needs to be differentiated from symptoms caused by VPA-
induced hyperammonemia (Perucca, 2002).  
 
 
2.3.8. Polycystic ovary syndrome (PCOS) 
Reproductive endocrine disorders have frequently been reported in women with 
epilepsy (Verrotti et al., 2011c). Polycystic ovaries are found on ultrasono-
graphy in ~20% of normal women and generally are not considered an abnormal 
feature (Taylor, 1998). On the other hand, PCOS is a disorder characterized by 
polycystic ovaries associated with hyperandrogenism, hypofertility, menstrual 
irregularities, hirsutism, acne, obesity, and reduced glucose tolerance. PCOS is 
the most common endocrine disorder in women of reproductive age, with a 
general prevalence among premenopausal women of 5–6% (Bilo and Meo, 
2006).  
A 1993 report from Isojärvi et al. was the first to describe the possible 
association between VPA use and PCOS in a large series of patients (Isojarvi et 
al., 1993). After this report, the possible association between PCOS, epilepsy, 
and VPA received widespread attention from the scientific community (Bilo 
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and Meo, 2006). A large body of evidence suggests that VPA treatment 
increases the incidence of PCOS (Isojarvi et al., 1996; Isojarvi et al., 1993; 
Isojarvi et al., 2001a; Morrell et al., 2002; Morrell et al., 2008; Sahota et al., 
2008), although some studies have reported no significant association (Bauer et 
al., 2000; Bilo et al., 1988; Luef et al., 2002a; Luef et al., 2002c; Murialdo et al., 
1998). This inconsistency has led to lively debate between research groups 
(Genton et al., 2001; Isojarvi et al., 2001b). Possible explanations for the discre-
pancy may be the small sample size of some studies, lack of randomization, and 
differences in PCOS definitions (Verrotti et al., 2011c). A recent meta-analysis 
of 11 studies showed that women with epilepsy who were taking VPA had an 
~1.95-fold risk of PCOS compared to women treated with other AEDs. 
However, due to the heterogeneity of studies included in the meta-analysis, the 
authors recommended that the result be confirmed in further prospective, 
randomized studies (Hu et al., 2011).  
Several theories have been proposed to explain the possible association of 
VPA treatment with PCOS. One theory is that VPA-induced weight gain leads 
to decreased peripheral insulin sensitivity and hyperinsulinemia. Insulin inhibits 
production of insulin-like growth factor 1 (IGF-1) binding protein 1 and sex 
hormone-binding globulin (SHBG) in the liver (Hamilton-Fairley et al., 1993), 
leading to an increased ovarian concentration of free IGF-1 (Cataldo, 1997). 
Insulin and IGF-1 stimulate thecal androgen production and reduce SHBG 
levels, thereby increasing free plasma testosterone levels (Hopkinson et al., 
1998). Therefore, hyperinsulinemia increases the secretion of ovarian androgen 
and promotes androgen bioavailability (Verrotti et al., 2011c). Moreover, VPA 
may directly stimulate ovarian androgen biosynthesis, probably by HDAC inhi-
bition, which promotes transcription of steroidogenic genes (Nelson-DeGrave et 
al., 2004). Finally, due to its inhibitory effect on the hepatic P450 enzyme system, 
VPA may impair the metabolism of sex steroids such as testosterone, hence 
provoking increased androgen levels (Isojarvi, 2008). 
 
 
2.3.9. Effects on offspring 
The first observations of teratogenic effects of VPA were reported in the early 
1980s (Gomez, 1981; Robert and Guibaud, 1982). Since then, data from dif-
ferent pregnancy registries have consistently shown that mothers who use VPA 
during pregnancy have a higher risk of major congenital malformations among 
their offspring (Campbell et al., 2014; Hernandez-Diaz et al., 2012; Tomson et 
al., 2011). Exposure to VPA during the first trimester is associated with 
increased risks of spina bifida, craniosynostosis, cleft palate, hypospadias, atrial 
septal defect, and polydactyly (Tomson et al., 2015b). The risk of major con-
genital malformations is generally two-to-three times higher for VPA compared 
to other AED monotherapies (Tomson et al., 2015b). Risk of fetal malfor-
mations among women treated with polytherapy depends mainly on whether the 
regimen includes VPA (Holmes et al., 2011; Vajda et al., 2010). Recent reports 
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emphasize that the teratogenic effect of VPA is dose related; the risk of major 
congenital malformations with VPA doses less than 700 mg/d seems to be 
comparable to that of other AEDs (Tomson et al., 2015a). 
There are reports of impaired intellectual and behavioral development among 
children who were exposed to VPA in utero. School-aged children of mothers 
who were treated with VPA during pregnancy had significantly lower verbal 
intelligence quotient scores than children exposed to CBZ, phenytoin, or not 
exposed to AEDs (Adab et al., 2004). In response to these data, in 2014 the 
European Medicines Agency strengthened its warnings on VPA use by females. 
However, epileptologists raised concerns about some of the recommendations, 
which would require women with epilepsy to fail on several less-appropriate 
medications before being prescribed VPA, which is the most effective AED for 
some syndromes (Tomson, 2015). Thereafter, the Commission on European 
Affairs of the International League Against Epilepsy and the European Academy 
of Neurology developed specific recommendations. Current recommendations 
maintain that VPA should be avoided in women with childbearing potential and 
should not be prescribed as a first-line treatment for focal epilepsy. For epilepsy 
syndromes that are most effectively treated by VPA, this drug could be offered 
to females after a risk-benefit assessment and discussion with the patient and/or 
her representatives. When possible, VPA doses not exceeding 500–600 mg/day 
are recommended, although higher doses may be necessary to attain seizure 
control (Tomson et al., 2015c).  
 
 
2.3.10. Inhibition of histone deacetylase 
VPA acts directly at the level of gene transcription by inhibiting HDAC and in-
creasing access to transcription sites (Chateauvieux et al., 2010). HDAC inhi-
bitors and VPA regulate innate and adaptive immune pathways, with possible 
anti-inflammatory effects (Shakespear et al., 2011). VPA-induced inhibition of 
HDAC can result in cell-cycle disruption, growth arrest, and apoptosis, which 
may explain the teratogenic action of the drug (Ornoy, 2009). In vitro and in 
vivo preclinical studies demonstrated strong antitumor effects of VPA against 
various cancers by modulating multiple pathways, including cell-cycle arrest, 
angiogenesis, apoptosis, and differentiation (Chateauvieux et al., 2010). VPA 
inhibits proliferation and induces differentiation of malignancies, such as 
leukemia, lymphoma, teratocarcinoma, and medulloblastoma. Clinically, VPA 
has been used to treat leukemia and some solid tumors (Chen et al., 2012). 
 
  
2.3.11. Weight gain 
In the medical community, VPA is widely thought to cause a weight gain 
(Table 1). Around 10–70% of patients with epilepsy on VPA treatment expe-
rience problems with body weight increase (Belcastro et al., 2013). Only two 
double-blind clinical studies have assessed weight change in VPA-treated 
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patients. Privitera et al. compared patients with new-onset seizures treated by 
CBZ, TPM, or VPA for 1 year, reporting mean weight increases of 2 and 5 kg 
in VPA-treated adults and children, respectively. CBZ was weight-neutral and 
TPM was related to weight loss (Privitera et al., 2003). Another study found 
significantly higher median weight gain after 32 weeks of treatment with VPA 
(5.4 ± 4.1 kg vs. baseline) compared to LTG (0.5 ± 5.0 kg vs. baseline) among 
patients with epilepsy (Biton et al., 2001). Results from other studies on weight 
gain in VPA-treated patients are rather ambiguous. Some support the occur-
rence of this side effect (Dinesen et al., 1984; El-Khatib et al., 2007; Isojarvi et 
al., 1996; Luef et al., 2002b; Morrell et al., 2003; Prabhakar et al., 2007), 
whereas others find no difference in weight among VPA-treated patients 
compared to controls (de Vries et al., 2007; Luef et al., 2002c; Pylvanen et al., 
2003; Pylvanen et al., 2006b; Stephen et al., 2001). Considering all of the 
published data on this topic, we assume that probably VPA causes weight gain. 
However, the real incidence and magnitude of this problem are unknown and 
should be investigated in specially designed, well-controlled, prospective 
clinical trials. With regard to potential risk factors, results from clinical studies 
suggest that women seem to be more prone to weight gain during VPA treat-
ment compared to men. For example El-Khatib et al. showed that women 
experienced weight gain more frequently and to a greater extent than did men 
(43.6% of women vs. 23.5% of men on VPA therapy had weight gain) (El-
Khatib et al., 2007). In female patients, the increase in body weight occurs more 
frequently in postpubertal girls taking VPA (Biton et al., 2003; Prabhakar et al., 
2007; Rattya et al., 1999), leading some authors to suggest that a mature (adult) 
endocrine system is necessary for development of VPA-related obesity (Verrotti 
et al., 2011b). Weight gain is usually observed within the first 3 months of VPA 
therapy and peaks by 6 to 12 months (Verrotti et al., 2011b). Some authors sug-
gest that patients may have gradual but progressive weight gain over years after 
VPA medication is started (Rattya et al., 1999). The influence of daily VPA 
dosage on weight gain was not specifically investigated. Available data suggest 
that there is no correlation between the degree of weight gain and the daily VPA 
dosage or serum VPA concentration (Verrotti et al., 2011b). Some studies 
showed that the risk of obesity on VPA therapy is higher in patients with higher 




Table 1. Weight change in VPA-treated adults and adolescents in recently published studies. 
Study No. of 
patients 
















25* 0.67* + CBZ, TPM + II 




30.1 ± 14.0 0.6* + LTG + I 




16 ± 3.0 0.67* + LTG + I 




24.9 ± 5.8 <5 + LTG – III 




19.1–79.0** 0.75–6.2** + No + IV 
Isojarvi et al., 
1996 








17–47** ≥2 – LTG – III 
Pylvanen et al., 
2003 








31.4 ± 11.9 6.4 ± 5.0 – Healthy 
controls 
– III 




34 ± 10** (F) 
35 ± 13** (M)
1.5 ± 0.7 (F) 
1.8 ± 0.5 (M) 
+ No – IV 
Luef et al., 
2002b 
22 (F) 31.2 ± 4.2 3–27** + CBZ, LTG – III 
Luef et al., 
2002c 
22 (F) 31 ± 4.4 13.5 ± 6.5 – CBZ, LTG, 
PRM 
– III 
Prabhakar et al., 
2007 
25 (F) 15–28** 1 + No + IV 
de Vries et al., 
2007 
43 (F) 14.9 ± 3.3 1–9.5** – Untreated – III 
* Median values; ** Range values. Rating scale of evidence for relevant studies: Class I – an adequately 
powered prospective, randomized, controlled clinical trial in a representative population, primary outcome 
(weight gain) is clearly defined; Class II – randomized controlled trial in a representative population, 
primary outcome (weight gain) is not clearly defined; Class III – all other controlled trials in a 
representative population, case-control or open-label studies, major confounding differences between risk 
groups that could affect outcome are described; Class IV – uncontrolled studies, case series, or expert 
reports (adopted from European Federation of Neurological Societies scoring system (Brainin et al., 2004).  
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2.4. Possible mechanisms relating valproic acid  
and weight gain 
According to the first law of thermodynamics, body weight cannot change if 
energy intake and energy expenditure are equal over time. Humans take in energy 
with food in the form of protein, carbohydrate, or fat. They expend energy 
through the resting metabolic state, which is the amount of energy necessary to 
fuel the body at rest and the energy expended through physical activity. Energy 
intake is fully controlled by human behavior, whereas energy expenditure is 
approximately 20–40% related to behavior (Hill et al., 2012). The weight 
change in patients on VPA therapy should be caused by a change in behavior: 
they will either eat more or decrease their physical activity. There are no pub-
lished data suggesting that the level of physical activity in VPA-treated patients 
should change. However, there are reports showing that these patients have 
increased appetite and higher frequency of carbohydrate cravings (Dinesen et 
al., 1984; El-Khatib et al., 2007; Verrotti et al., 1999). Thus, VPA most likely 
changes patient behavior by increasing the appetite, resulting in energy balance 
disruption and subsequent weight gain. 
Pathogenic mechanisms underlying VPA-induced weight gain are still 
unclear. Most likely, these mechanisms are multifactorial. The balance between 
energy intake and expenditure is a complex process that is regulated by various 
appetite-regulating neuropeptides and cytokines that act within the hypo-
thalamus. Some hypotheses have been proposed to explain the effect of VPA on 
weight increase (Belcastro et al., 2013; Verrotti et al., 2011b; Verrotti et al., 
2009) (Figure 3). 
1. VPA is a well-known promotor of histone acetylation and modulates expres-
sion of many genes. In adipocytes, VPA suppressed the gene expression of 
adiponectin (Qiao et al., 2006), a biologically active mediator that modulates 
insulin sensitivity. Adiponectin plasma concentrations were negatively cor-
related with weight and were significantly lower in obese patients with epi-
lepsy compared to patients who did not gain weight (Greco et al., 2005). It is 
not clear, however, whether hypoadiponectinemia in patients with epilepsy 
was the cause or consequence of increased weight. Another important 
signaling peptide that regulates body weight is leptin, which is produced by 
adipocytes. Leptin regulates energy balance by inhibiting hunger. Leptin 
plasma concentration and mRNA expression in adipose tissue were directly 
related to obesity severity, as an increase of fat mass was associated with an 
increase of leptin levels (Verrotti et al., 2011b). In vitro, VPA reduced leptin 
mRNA levels and secretion of leptin protein, which probably can induce 
enhanced appetite in patients on VPA treatment (Lagace et al., 2004). Many 
clinical studies, however, reported increased serum levels of leptin in patients 
who gained weight during VPA treatment (Greco et al., 2005; Hamed et al., 
2009; Rauchenzauner et al., 2008; Verrotti et al., 1999). This finding could 
be explained by leptin resistance secondary to weight increase. Leptin resi-
stance is reduced sensitivity to leptin action, resulting in an inability to 
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detect satiety despite high energy storage. In the absence of VPA-induced 
obesity, no significant changes in leptin levels have been observed (Verrotti 
et al., 2009). 
2. VPA has been suggested to cause dysregulation of the hypothalamic system 
(Lakhanpal et al., 2011; Lakhanpal and Kaur, 2007). VPA-mediated enhan-
cement of GABAergic transmission within the hypothalamic axis may 
increase appetite (Biton et al., 2003). VPA may also modify transcription of 
adipokine (resistin, fasting-induced adipose factor) genes, which are expres-
sed in the brain and pituitary and are involved in central energy metabolism 
(Brown et al., 2008; Munzberg and Myers, 2005). 
3. Turnbull et al. demonstrated a moderate fall in blood glucose levels after 
oral or intraperitoneal administration of VPA in Wistar rats (Turnbull et al., 
1985). Subsequent preclinical studies confirmed this effect (Akindele et al., 
2015; Khan and Jena, 2016; Khan et al., 2016; Terasmaa et al., 2011). 
Several clinical studies reported lower blood glucose levels in VPA-treated 
patients compared to controls (Aydin et al., 2005; Demir and Aysun, 2000; 
Martin et al., 2009; Pylvanen et al., 2006a). In some patients, lower blood 
glucose concentration was independent of insulin concentration. This finding 
suggests that VPA may modulate glucose homeostasis by an insulin-inde-
pendent mechanism (Demir and Aysun, 2000; Martin et al., 2009). Mild 
hypoglycemia in VPA-treated patients can cause an increase in appetite, 
leading to weight gain. 
4. Many studies have reported hyperinsulinemia among patients on VPA 
treatment (Verrotti et al., 2011b). There is no general agreement on whether 
hyperinsulinemia is a result of weight gain and insulin resistance (IR) 
following VPA treatment (Belcastro et al., 2013) or whether VPA treatment 
directly causes hyperinsulinemia and IR, which lead to weight gain in some 
patients (Luef et al., 2003; Pylvanen et al., 2006a). Some studies showed that 
high blood insulin concentrations occur more frequently among patients who 
have already gained weight compared to those who have not, suggesting that 
hyperinsulinemia is secondary to weight gain (Isojarvi et al., 1996; Luef et 
al., 2002c; Pylvanen et al., 2002; Stephen et al., 2001; Verrotti et al., 1999). 
On the other hand, Pylvanen et al. found that both obese and lean patients 
taking VPA had hyperinsulinemia, suggesting that IR development is a factor 
that leads to weight increase. Other authors proposed that hyperinsulinemia 
in these patients may be the result of disturbed insulin metabolism in liver, 
caused by VPA, resulting in higher insulin concentrations in peripheral cir-
culation (Pylvanen et al., 2006a). Luef et al. reported that VPA can directly 
stimulate pancreatic β-cells and cause insulin secretion in vitro (Luef et al., 
2003). Both theories are probably true; at the start of treatment, VPA might 
increase pancreatic insulin secretion and/or decrease insulin degradation in 
the liver, leading to hyperinsulinemia and decreased blood glucose levels, 
resulting in enhanced appetite and energy storage. In patients who exhibit 
weight increase, IR could develop, which also might lead to an elevation of 






























































5. Valproate is a branched-chain fatty acid. Thus, VPA administration could 
lead to increased plasma levels of free fatty acids (FFAs), which are key 
modulators of endogenous glucose production (Luef et al., 2002b). Elevated 
FFA levels play an important role in IR development. Dietary intake and 
plasma levels determine the fatty acid content in cell membranes, and higher 
levels of membrane-saturated fatty acids could impair the action of insulin 
(Verrotti et al., 2009). VPA may inhibit β-oxidation of fatty acids in mito-
chondria, thereby shifting substrate use from fats to carbohydrates and 
decreasing glucose concentrations (Demir and Aysun, 2000). The increased 
level of FFAs may directly influence the hypothalamus, which regulates 
food intake and whole-body glucose handling (Schwartz et al., 2000). 
Intracerebroventricular infusion of the long-chain fatty acid oleic acid in rats 
caused rapid reductions in food intake and inhibited endogenous glucose 
production (Obici et al., 2002).  
 
 
2.5. Metabolic syndrome in patients with epilepsy 
MS is a constellation of metabolic risk factors, which include central obesity, 
atherogenic dyslipidemia, hypertension, and elevated blood glucose levels 
associated with IR (Reaven, 1988). As it is associated with an approximately 
twofold increased risk of cardiovascular and cerebrovascular diseases (Isomaa 
et al., 2001; Lakka et al., 2002), MS represents a major economic burden and 
public health problem (Fu et al., 2007; Wang et al., 2010).  
The overall mortality rate among people with epilepsy is two to three times 
higher than that of the general population (Nevalainen et al., 2014). Epilepsy is 
associated with a higher risk of cardiovascular diseases (Gaitatzis et al., 2004; 
Janszky et al., 2009), which undoubtedly contributes to the increased mortality 
rate. In people with epilepsy, a sedentary lifestyle and AED use contribute to 
obesity and MS (Ben-Menachem, 2007; Steinhoff et al., 1996). In addition, the 
comorbidity profile differs between patients with epilepsy and healthy subjects, 
as patients more frequently have psychiatric disorders or brain damage-related 
symptoms, which could influence the risk of MS.  
Numerous studies have explored the effects of different anticonvulsants on 
specific metabolic and anthropometric parameters. However, only a few studies, 
with conflicting results, have examined the presence of MS in patients with 
epilepsy. Some of these studies focused only on specific populations, such as 
females (Kim and Lee, 2007) or children (Dhir et al., 2015; Verrotti et al., 2010), 
whereas others studied different metabolic side effects of AEDs, such that the 
occurrence of MS was assessed only indirectly (Luef et al., 2009; Pylvanen et 
al., 2006b). Verrotti et al. (Verrotti et al., 2010) showed that the presence of MS 
in VPA-treated children and adolescents who became obese did not differ from 
MS prevalence in otherwise healthy overweight subjects. Pylvänen et al. reported 
similar frequencies of MS between VPA-treated adults and control subjects 
(Pylvanen et al., 2006b). A study evaluating the prevalence of MS among Chinese 
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adult obese patients with epilepsy treated with VPA showed a tendency toward 
a higher risk of MS compared to obese control subjects, although this difference 
was not statistically significant (Fang et al., 2012). On the other hand, Kim and 
Lee reported that females with epilepsy on VPA monotherapy more frequently 
have MS compared to females treated with CBZ, LTG, or TPM (Kim and Lee, 
2007). In a recent study from India the use of VPA was associated with 
significant risk of MS in patients with epilepsy, attending outpatient clinic (Nair 
et al., 2016). Furthermore, NAFLD, which is the hepatic manifestation of MS, 
occurred more frequently in patients on VPA treatment compared to patients on 
CBZ or LTG monotherapy (Luef et al., 2009).  
In people with epilepsy who are indicated for AED treatment, physicians fre-
quently choose between different anticonvulsants. Information on the potential 
relationship between different AEDs and MS risk could help physicians in this 
decision-making process. As is apparent, current knowledge about this topic is 
insufficient and inconsistent. 
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3. AIMS OF THE STUDY 
1. To evaluate the prevalence of MS and its components in VPA-treated patients 
with epilepsy in Estonia compared to the general population (Paper I). 
2. To compare the risk of MS and evaluate related factors for MS among 
people with epilepsy treated with VPA or CBZ (Paper II). 
3. To characterize the effect of acute IV VPA treatment on the blood levels of 
glucose, insulin, and C-peptide after first VPA exposure in naive patients 
with newly diagnosed epilepsy (Paper III).  
4. To analyze the effects of chronic VPA treatment on the peripheral blood 
gene expression profile induced by 3 months of treatment in patients with 
newly diagnosed epilepsy (Paper IV). 
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4. SUBJECTS AND METHODS 
All the studies included in this thesis have been approved by Ethics Review 
Committee on Human Research of the University of Tartu. An informed con-
sent has been obtained from all study participants. 
 
 
4.1. Study design 
Papers I and II 
The study design was cross-sectional population-based study including patients 
with epilepsy treated with VPA, CBZ and control subjects from southern Estonia. 
 
Papers III and IV 
Case-crossover study including patients with newly diagnosed epilepsy, who 
were indicated for VPA therapy. 
 
 
4.2. Prevalence and risk factors of metabolic  
syndrome in patients treated with valproate  
and carbamazepine (Papers I and II) 
4.2.1. Subjects of the studies 
The study was carried out in the Departments of Neurology and Internal 
Medicine, Tartu University Hospital, Estonia. 
Using the prescription database of the Estonian Health Insurance Fund, 
patients with epilepsy from six southern Estonian counties (including the city of 
Tartu and Tartu County) who were prescribed VPA and patients with epilepsy 
from the city of Tartu and Tartu County who were prescribed CBZ were 
identified. Exclusion criteria for patients with epilepsy were as follows: age 
≤ 18 years; VPA or CBZ monotherapy for < 3 months; polytherapy with other 
AEDs; pregnancy. As physical inactivity is a major risk factor of MS, and as the 
aim of the study was to evaluate possible relationships between AEDs, epilepsy 
syndromes, and MS risk, patients with severe physical or mental disabilities 
related to severe brain damage were not included. Specifically, patients who 
lived at nursing homes or who were dependent at or outside the home were 
excluded. Study participants should be able to engage in normal occupational 
and social activities, despite minor physical or mental deficits. Patients with 
endocrine disturbances, such as diabetes or thyroid dysfunction, were not 
excluded.  
The data was collected between 1 January and 31 December 2012 for VPA-
treated patients as well as between 1 December 2014 and 1 September 2015 for 
patients treated with CBZ.  
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A total of 384 (206 men, 178 women) and 484 (292 men, 192 women) patients 
with epilepsy diagnoses who had received VPA or CBZ treatment, respectively, 
were initially identified. Applying the data collection methods, 118 VPA-treated 
patients (63 men, 55 women) and 95 CBZ-treated patients (55 men, 40 women) 
were included in the final study sample. From the initial drug prescription 
database, 17 (4.4%) VPA-treated subjects and 138 (28.5%) CBZ-treated patients 
were not included in the final sample due to severe physical or mental disability 
related to brain damage caused by severe head injury, cerebrovascular disease, 
progressive brain neoplasm, pre- or perinatal risk factors, central nervous system 
infection, or other factors (Figure 4). Clinical characteristics of the patients are 
summarized in Table 2. 
The control group comprised subjects who participated in a population-based 
cross-sectional multicenter study of MS prevalence conducted in southern 
Estonia between November 2008 and May 2009 (Eglit et al., 2012). Control 
subjects were adults who were randomly selected from four general practices. 
An invitation letter about the study was sent to each participant representing 
control group. The total response rate was 53.2% (493 control subjects). The 
control subjects were representative of the general Estonian population in terms 
of age and gender. Distributions of the ethnic groups and the socioeconomic 
status of inhabitants are similar among the various counties in southern Estonia.  
 
 
4.2.2. Collection of anthropometric and laboratory data 
All patients with epilepsy were contacted by phone and those who met the 
inclusion criteria were invited to the outpatient clinic of the Department of 
Neurology at Tartu University Hospital. The author of this thesis interviewed 
and clinically examined all patients. The medical histories of participants were 
documented during the evaluation meeting. Concomitant diseases of relevance 
to the study, including known endocrinopathies, lipid metabolism disorders, and 
vascular diseases, were noted. Blood pressure, waist circumference, weight, and 
height were measured. Body mass index (BMI) was calculated as the weight (kg) 
divided by height squared (m2). Blood samples were obtained in the morning 
(between 08:00 and 11:00) after an overnight fast (≥10 h) for the analysis of 
serum insulin, C-peptide, high-density lipoprotein cholesterol (HDL-C), tri-
glyceride (TG), and fasting blood glucose concentrations. Patients with unmea-















































































































































































































































































































































































































































































































































































































































































































































































During the face-to-face interviews and the review of previous medical history, 
the patients’ epilepsy diagnoses were re-evaluated, and the date of the last 
seizure was recorded. Epileptic syndromes were classified based on the recently 
proposed International League against Epilepsy classification (Berg et al., 
2010). The date of initiation, duration, and current dosage of VPA or CBZ treat-
ment were recorded. Patients were asked whether they had noticed any change 
in body weight after initiation of VPA or CBZ treatment. The final regression 
analysis, comparing MS risk factors of patients treated with VPA or CBZ, 
included concomitant conditions as a covariate. Concomitant conditions included 
psychiatric comorbidities treated with antidepressants and/or antipsychotics, and 
thyroid dysfunction. The regular use of medications for the treatment of arterial 
hypertension, dyslipidemia, or previously diagnosed diabetes was not considered 
as an independent covariate in the regression analysis, because the use of these 




Plasma glucose levels were measured by the hexokinase method. HDL-C and 
TG concentrations were measured by an enzymatic colorimetric assay. VPA and 
CBZ concentrations were measured by fluorescence polarization assay (COBAS 
INTEGRA 800 Plus Analyzer; Roche, Basel, Switzerland). In control subjects, 
plasma insulin concentrations were measured by a chemiluminescent assay 
(Immulite 2000 Analyzer; Siemens Healthcare Diagnostics, Deerfield, IL, USA), 
whereas in patients, they were measured by an electrochemiluminescent assay 
(COBAS 6000 Analyzer; Roche). To compare plasma insulin corrected con-
centrations between patients and controls, the difference between the two 
measurement assays was calculated according to the Clinical and Laboratory 
Standards Institute’s guidelines (Wayne, 2013). Plasma C-peptide concent-
rations were measured only in patients by an electrochemiluminescent assay 
(COBAS 6000 Analyzer; Roche). 
 
 
4.2.4. Definition of metabolic syndrome 
MS was diagnosed based on the presence of at least three of the following 
National Cholesterol Education Program Adult Treatment Panel III criteria 
(Grundy et al., 2005): waist circumference ≥ 102 cm in men and ≥ 88 cm in 
women, BP ≥ 130/85 mmHg or antihypertensive medication use, fasting glucose 
concentration ≥ 5.6 mmol/L or previously diagnosed diabetes, TG concentration 
≥ 1.7 mmol/L or lipid-regulating medication use, and HDL-C concentration 
< 1.03 mmol/L in men and < 1.3 mmol/L in women or drug treatment for 
reduced HDL-C. IR was estimated by the homeostasis model assessment-
estimated insulin resistance (HOMA-IR) index, calculated with the following 
equation: fasting glucose (mmol/L) × fasting insulin (mU/L) / 22.5. Patients 
with BMIs ≥ 25 kg/m2 were categorized as overweight. 
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4.2.5. Statistical analysis 
Descriptive analytical methods, such as the calculation of means, standard 
deviations (SDs), medians, and interquartile ranges (IQRs), were used for con-
tinuous variables, depending on the distribution.  
Logistic regression model for the risk of MS and its components in patients 
treated with VPA compared to control subjects and with CBZ compared to 
control subjects was adjusted by age and sex. Age- and sex-adjusted linear 
regression models were used to compare anthropometric and laboratory data 
between VPA-treated patients and control subjects, as well as between CBZ-
treated patients and controls. Linear regression models adjusted by age, sex, 
epilepsy etiology, seizure frequency, treatment duration and concomitant 
diseases were used to compare anthropometric and laboratory data between 
VPA- and CBZ-treated patients.  
Multiple logistic regression analysis was performed to identify factors 
associated with MS development in VPA- and CBZ-treated patients. The final 
multiple logistic regression model, which compared the risk for MS between 
VPA- and CBZ-treated patients was adjusted for age, sex, epilepsy etiology, 
seizure occurrence in the last year, treatment duration, and concomitant diseases.  
A receiver operating characteristic (ROC) analysis was conducted to 
evaluate whether BMI and HOMA-IR had similar predictive abilities for MS in 
VPA-treated patients and control subjects.  
The prevalence of MS in VPA-treated patients was calculated by the indirect 
method of standardization, considering the age and sex distribution of the 
control group as the standard. Odds ratios (ORs) and 95% confidence intervals 
(95% CIs) are reported. The R software package (The R Foundation for Statistical 
Computing; version 2.15.1) was used for statistical analyses. Differences with p 
< 0.05 were considered statistically significant. 
 
 
4.3. The effect of acute intravenous valproate  
treatment on the glucose, insulin and  
C-peptide metabolism (Paper III) 
4.3.1. Subject selection 
Sixteen consecutive adult patients from the outpatient clinic of the Tartu 
University Hospital were recruited between March 2011 and March 2015. These 
individuals were newly diagnosed with epilepsy and were indicated for VPA 
therapy. Patients were excluded if they were treated with any medication, had a 
history of diabetes, a cardiovascular, hepatic, renal, oncologic or progressive 
neurological disease that could impact glucose or insulin metabolism, evidence 
of progressive lesions on computed tomography or magnetic resonance imaging. 
Main subject characteristics including age and epileptic syndrome are sum-
marized in Table 3. Seizures and epileptic syndromes were classified based on 
the criteria proposed by the ILAE (Berg et al., 2010). 
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4.3.2. Study design 
The study protocol assumed two visits for each patient. These visits began at 
8 a.m. following an overnight fast. During the first visit, the oral glucose tole-
rance test (OGTT) was performed using a 75 g glucose load. Plasma glucose, 
serum insulin, and C-peptide levels were measured in the fasting state, as well 
as one and two hours postprandially. At the second visit, patients received VPA 
(Orfiril, Desitin) administered IV during 20 minutes at a load of 900–1800 mg 
diluted in 100 ml 0.9% NaCl. Directly following VPA infusion, the OGTT was 
performed. Serum VPA concentrations were measured directly following VPA 
infusion, as well as one and two hours postprandially. Cardiovascular para-
meters, such as heart rate and blood pressure, as well as signs of irritation at the 
injection site were closely monitored. For every single patient, the number of 
days between the two visits varied from 1 to 7 days. The second OGTT was 
performed as fast as possible after first OGTT in order to diminish the potential 
for additional confounding factors to affect the results. A deadline of 7 days 















Male 6 22 ± 3.5 6 0 26.9 ± 5.8 
Female 10 28.5 ± 9.1 8 2 22.9 ± 2.9 
All 16 26 ± 8.0 14 2 24.4 ± 4.5 




4.3.4. Statistical analysis 
The data are presented as mean ± standard deviation (SD). Statistical signi-
ficance was evaluated by paired t-test. P values <0.05 were considered to be sta-
tistically significant. The R software package (The R Foundation for Statistical 
Computing; version 2.15.1) was used for statistical analyses. 
 
Plasma glucose levels were measured using the hexokinase method. VPA 
concentrations were measured by fluorescence polarization assay (COBAS 
INTEGRA 800 Plus Analyzer; Roche, Basel, Switzerland). Plasma insulin and 
C-peptide concentrations were measured using an electrochemiluminescent 
assay (COBAS 6000 Analyzer; Roche, Basel, Switzerland). 
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4.4. The effect of chronic valproate treatment  
on peripheral blood gene expression (Paper IV) 
4.4.1. Subjects 
Nine otherwise healthy subjects with newly diagnosed epilepsy and for whom 
VPA treatment was indicated were enrolled. Patients were excluded if there was 
a history or evidence of noncompliance with medical regimens; treatment with 
any medication other than VPA, including hormonal contraception; evidence of 
a cardiovascular, hepatic, renal, oncologic, or progressive neurological disease 
that could have an impact on blood RNA expression; evidence of progressive 
lesions on computed tomography or magnetic resonance imaging; or if the 
patient was pregnant.  
The main subject characteristics, including epileptic syndrome and VPA 
dose, are summarized in Table 4. Before and 3 months after the start of VPA 
treatment, the weight and height were measured, and the BMI was calculated. 
 


















F 38 Gen 600 12.5 21.3 21.8 
F 38 Str/met 900 15 21.8 21.8 
M 21 Gen 900 8.3 34.5 34.5 
M 21 Gen 600 6.9 24.1 25.5 
M 18 Gen 600 9.7 20.0 23.6 
F 21 Gen 600 12.8 17.7 18.8 
F 33 Gen 600 11.8 20.2 21.0 
F 18 Gen 600 9.8 19.5 19.8 
F 32 Str/met 1200 15.8 24.8 24.5 
Gen, genetic; Str/met, structural/metabolic; VPA, valproate; BMI, body mass index. 
 
 
4.4.2. Sample collection and RNA preparation 
Blood samples were collected during two visits, before and around 3 months 
after the start of treatment with VPA. The daily VPA dose was 600 to 1200 mg 
(mean dose: 11.4 ± 2.8 mg/kg). Blood samples were collected into Tempus tubes 
(Applied Biosystems, Foster City, USA). Blood was frozen and stored until 
further processing. RNA was extracted from whole blood with an RNA extraction 




4.4.3. Statistical analysis 
Differential gene expression was analyzed by using the EdgeR package with 
non-normalized raw counts after the quality control of samples. EdgeR is a very 
flexible tool for RNA sequencing data analysis, which uses model-based scale 
normalization, dispersion estimates, negative binomial model fitting, and testing 
procedures to determine the differential expression of genes (McCarthy et al., 
2012; Robinson et al., 2010). As our sample contains paired samples (pre- and 
post-VPA), a paired testing approach was used. General linear modeling was 
applied, with subjects being added to the contrast matrix. The general linear 
modeling likelihood ratio test was applied to compare pre- and post-VPA results. 
False discovery rate adjustment was used for multiple testing correction (Storey 
and Tibshirani, 2003). The threshold for statistical significance was an adjusted 
false discovery rate of 0.1. 
 
 
4.4.4. Functional analysis of differentially expressed genes 
Functional network analysis is used to identify the biological functions that are 
most significantly related to the molecules in a network. To define the functional 
networks of differentially expressed genes, the data were analyzed by using the 
Ingenuity Pathway Analysis (Ingenuity Systems, www.ingenuity.com), which 
calculates a significance (network) score for each network. This score indicates 
the likelihood that the assembly of a set of focus genes in a network could be 
explained by random chance alone (e.g., a score of 2 indicates that there is a 1 
in 100 chance that the focus genes are together in a network due to random 
chance). A data set containing the Affymetrix probe-set identifiers and their cor-
responding fold change (log2) values was uploaded into the Ingenuity Pathway 
Analysis software. Each gene identifier was mapped to its corresponding gene 
object in the Ingenuity Pathways Knowledge Base to identify molecules whose 
expression was significantly differentially regulated. These focus genes (or 
Network Eligible molecules) were overlaid onto a global molecular network 
developed from information contained in the Ingenuity Pathways Knowledge 
Base. Networks of these focus genes were then algorithmically generated on the 
basis of their connectivity. 
A network is a graphical representation of the molecular relationships between 
genes or gene products (represented as nodes). The biological relationship 
between two nodes is represented as an edge (line). All edges are supported by at 
least one reference from the literature, or from canonical information stored in 




5.1. Clinical characteristics of patients and control subjects 
Median ages of patients treated with VPA and CBZ and control subjects were 
32 years (IQR, 24–45 years), 56 years (IQR, 43–66 years) and 47 years (IQR, 
35–59 years), respectively. In the final sample, most of the VPA-treated patients 
had a genetic epilepsy etiology (P < 0.0001), whereas CBZ-treated patients more 
frequently had a structural or metabolic cause of epilepsy (P < 0.0001) (Table 2). 
Twenty-five (11.7%) patients with epilepsy had psychiatric comorbidities that 
were treated with antidepressants and/or antipsychotics. Five (2.3%) patients 
had been diagnosed previously with thyroid dysfunction. Nine (4.2%) patients 
had been previously diagnosed with diabetes, three of them were treated with 
VPA and six patients were treated with CBZ. 
 
 
5.2. Prevalence of metabolic syndrome and  
it’s components in valproate- and carbamazepine-treated 
patients with epilepsy 
The crude prevalence of MS in adult patients with epilepsy who received VPA 
monotherapy was 20.3% (95% CI, 13.7–28.9%), with a prevalence of 22.2% 
(95% CI, 13.1–34.8%) in men and 18.2% (95% CI, 9.5–31.4%) in women. The 
prevalence of MS in VPA-treated patients, weighted by the age and sex 
distribution of the control cohort, was 25.8% (95% CI, 18.4–34.8%). The 
prevalence of MS in the control group was 27.9% (95% CI, 24.0–32.1%). In the 
final multiple logistic regression, after adjustment for age and sex, the risk of 
MS in VPA-treated patients was not increased (OR = 1.00; 95% CI, 0.59–1.68; 
P = 0.998). However, a larger proportion of VPA-treated patients had abnormal 
diastolic BP (≥85 mmHg) compared with control subjects (OR = 1.86; CI 1.15–
3.03; P = 0.011; Table 5). The risk of MS in CBZ-treated patients compared to 
controls was also not increased (OR = 1.23; CI 0.76–1.99; P = 0.407). Patients 
treated with CBZ had increased risk of high blood pressure, and high fasting 
blood glucose concentration. However, the occurrence of abnormally low HDL-C 
in these patients was significantly lower than in controls (Table 5). 
 
 
5.3. Comparison of anthropometric and metabolic 
parameters in valproate-treated patients and controls 
BMI did not differ between VPA-treated patients and control subjects 
(P = 0.295); however, VPA-treated patients had higher fasting serum insulin 
levels compared to control subjects (P < 0.0001). The HOMA-IR index was 
higher in patients than in control subjects (P = 0.0001). These differences 
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persisted when only normal-weight subjects from both cohorts were compared 
(P = 0.010 for insulin and P = 0.031 for HOMA-IR). Fasting plasma glucose 
concentrations tended to be lower in patients than in control subjects, although 
this difference was not significant (P = 0.169). The HDL-C and TG levels were 
similar in patients and control subjects (Table 6). 
 
Table 5. Logistic regression model for metabolic syndrome and its components in 
patients treated with valproate compared to control subjects and with carbamazepine 









95% CI P 
Waist circumference 0.75 0.47–1.22 0.248 0.79 0.49–1.27 0.328 
 men, >102 cm 0.89 0.45–1.75 0.90 0.90 0.47–1.72 0.756 
women, >88 cm 0.64 0.32–1.26 0.67 0.67 0.33–1.36 0.267 
HDL-C 0.95 0.57–1.59 0.851 0.13 0.04–0.43 0.001 
 men, <1.03 mmol/L 1.31 0.63–2.69 0.20 0.20 0.05–0.88 0.033 
women, <1.30 mmol/L 0.76 0.36–1.63 0.07 0.07 0.01–0.59 0.014 
Triglycerides  
≥ 1.7 mmol/L
1.34 0.80–2.24 0.267 1.18 0.69–2.03 0.539 
Fasting glucose  
≥ 5.6 mmol/L
0.78 0.46–1.31 0.352 1.86 1.15–2.99 0.011 
Systolic blood pressure  
≥ 130 mmHg
1.54 0.91–2.60 0.112 1.80 1.06–3.04 0.029 
Diastolic blood pressure 
≥ 85 mmHg 
1.86 1.15–3.03 0.011 2.16 1.33–3.51 0.002 
Metabolic syndrome 1.00 0.59–1.68 0.998 1.23 0.76–1.99 0.407 
Odds ratios (ORs) for metabolic syndrome and its components in valproate-treated, as well as in 
carbamazepine-treated patient cohort compared to controls and adjusted for age and sex. 









Table 6. Anthropometric and laboratory data in valproate-treated patients and control 
subjects 





BMI (kg/m2) 26.38±5.34 28.18±6.16 0.295 
Fasting glucose (mmol/L) 5.18±0.78 5.43±0.82 0.169 
Fasting insulin (mU/L) 9.10±8.51 6.35±5.52 <0.0001 
HOMA-IR 2.21±2.01 1.60±1.4 <0.001 
HDL-C (mmol/L) 1.51±0.49 1.53±0.45 0.581 
Triglycerides (mmol/L)  1.34±0.91 1.31±0.72 0.375 
Data presented as means ± standard deviations.  
BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance; VPA, 
valproate. 
P values were calculated after comparison of parameters between cohorts using multiple linear 
regression model adjusted for age and sex. 
 
 
5.4. HOMA-IR predictive ability for metabolic  
syndrome occurrence in valproate-,  
carbamazepine-treated patients and controls 
ROC analysis showed that BMI and HOMA-IR similarly predicted MS occur-
rence in control subjects, with areas under the ROC curve (AUCs) of 0.847 and 
0.848 (P = 0.97), respectively (Figure 5). The predictive ability of HOMA-IR 
was lower than that of BMI in VPA-treated patients, with AUCs of 0.808 and 
0.897 (P = 0.05), respectively (Figure 6). In CBZ-treated patients the difference 
of predictive ability of HOMA-IR and BMI was statistically not significant  
(P = 0.36) (Figure 7). 
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Figure 5. Receiver 
operating characteristic 
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5.5. Comparison of risk factors for metabolic  
syndrome in epilepsy patients treated  
with valproate or carbamazepine 
Stepwise logistic regression analysis revealed no significant correlation between 
MS development in patients with epilepsy and clinical characteristics, such as 
sex, epilepsy etiology, treatment with VPA or CBZ, seizure occurrence in the 
last year, HOMA-IR, and concomitant diseases. One of the factors to be signi-
ficantly correlated with the occurrence of MS in people with epilepsy was the 
patient’s age, which showed a positive correlation (OR = 1.03; 95% CI, 1.01–
1.06; P = 0.007). There was no correlation between the daily dosage of medi-
cation and the risk of MS in patients on CBZ treatment (P = 0.948). In VPA-
treated patients, a trend toward a positive correlation between drug dose and 
risk of MS was observed. However, this correlation did not reach statistical 
significance (OR = 1.11; 95% CI, 0.99 – 1.24; P = 0.075). Longer durations of 
VPA treatment tended to increase the risk of MS (OR = 1.01; 95% CI, 1.0–1.02; 
P < 0.01), however the duration of CBZ-treatment was not correlated to the MS 
risk (P = 0.941). In the final multiple logistic regression, after adjustment for age, 
the risk of MS in CBZ-versus VPA-treated patients was not increased 
(OR = 1.30; 95% CI, 0.65–2.62; P = 0.459). After adjustment of this model for 
other parameters, including sex, epilepsy etiology, seizure occurrence in the last 
year, treatment duration, and concomitant diseases, this difference was even less 
pronounced (OR = 0.99; 95% CI, 0.43–2.26; P = 0.979). Females treated with 
Figure 7. Receiver 
operating characteristic 




(HOMA-IR) and body 
mass index (BMI) 
values in 
carbamazepine (CBZ)-
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and HOMA-IR curves 
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logistic regression to 
determine the 
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syndrome (MS) in 
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the curve. 
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VPA tended to have a higher risk of MS (OR = 1.48; 95% CI, 0.50–4.41; 
P = 0.485) compared to males (OR = 0.74; 95% CI, 0.28–1.96; P = 0.551), 
although this difference was not statistically significant (Table 7). 
Regarding individual components of MS, a lower proportion of CBZ-treated 
patients had abnormally low HDL-C levels (OR = 0.10; 95% CI, 0.02–0.42; 
P = 0.002). This effect was more pronounced in women (OR = 0.02; 95% CI, 
0.001–0.22; P = 0.002) compared to men (OR = 0.47; 95% CI, 0.07–2.99; 
P = 0.425). A higher proportion of VPA-treated females had waist circumference 
values exceeding 88 cm (OR = 5.51; 95% CI, 1.05–29.01; P = 0.044). A lower 
proportion of VPA-treated patients had abnormally high FBG concentrations 
(OR = 0.30; 95% CI, 0.13–0.69; P = 0.004, Table 7). Overall, patients on VPA 
treatment had lower concentrations of HDL-C (P < 0.0001) and tended to have 
lower concentrations of fasting glucose (P = 0.055, Table 8). 
 
Table 7. Logistic regression model for metabolic syndrome and its components in 
patients treated with carbamazepine compared to valproic acid. 
Component OR 95% CI P 
Waist circumference 
   men, >102 cm 











   men, <1.03 mmol/L 










Triglycerides ≥ 1.7 mmol/L 0.78 0.33–1.87 0.577 
Fasting glucose ≥ 5.6 mmol/L 3.39 1.46–7.85 0.004 
Systolic blood pressure ≥ 130 mmHg 1.19 0.50–2.86 0.694 
Diastolic blood pressure ≥ 85 mmHg 1.13 0.51–2.47 0.768 
Metabolic syndrome  0.99 0.43–2.26 0.979 
Odds ratios (ORs) for metabolic syndrome and its components in carbamazepine- compared to the 
valproate-treated patients adjusted for age, gender, epilepsy etiology, seizure frequency, treatment 
duration, and concomitant diseases.  











BMI (kg/m2) 26.38±5.34 28.91±5.88 0.996 
Waist circumference (cm) 87.41±16.16 96.04±16.27 0.729 
Fasting glucose (mmol/L) 5.18±0.78 5.75±0.87 0.055 
Fasting insulin (mU/L) 10.23±8.88 11.18±6.75 0.956 
C-peptide (nmol/L) 0.79±0.38 0.84±0.32 0.407 
HOMA-IR 2.48±2.40 2.90±1.90 0.729 
HDL-C (mmol/L) 1.51±0.49 1.89±0.63 <0.0001 
Triglycerides (mmol/L)  1.34±0.91 1.49±1.55 0.632 
Data are presented as means ± standard deviations.  
VPA, valproate; CBZ, carbamazepine; BMI, body mass index; HOMA-IR, homeostasis model 
assessment of insulin resistance; HDL-C, high-density lipoprotein cholesterol. 
P values were calculated after comparison of parameters between cohorts using multiple linear 
regression model adjusted for age, gender, epilepsy etiology, seizure frequency, treatment 
duration, and concomitant diseases. 
 
 
5.6. The effect of acute intravenous valproate treatment 
on the glucose, insulin and C-peptide blood levels 
Plasma glucose levels on the 120 minute of OGTT session following infusion of 
VPA were significantly lower than those measured during OGTT without VPA 
treatment (4.28 ± 0.94 mmol/l vs. 4.75 ± 1.09 mmol/l respectively, P = 0.038). 
However, the concentrations of insulin and C-peptide did not differ significantly 
between the two measurements (Table 9). Overall, the administration of IV 
VPA was well tolerated in the patients, with no significant changes observed in 
heart rate or blood pressure. Of the 16 patients evaluated, three complained of 
moderate paresthesia or pain at the site of the injection. 
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Table 9. Oral glucose tolerance test in patients before the start of VPA treatment and 
immediately after the first intravenous VPA dose. 
 Basal OGTT OGTT after IV VPA P value 
Glucose (mmol/L) 
Fasting 5.15 ± 0.46 5.06 ± 0.45 0.381 
60 min pp 5.71 ± 1.25 6.01 ± 1.75 0.385 
120 min pp 4.75 ± 1.09 4.28 ± 0.94 0.038 
Serum insulin (mU/L) 
Fasting 9.64 ± 6.69 13.66 ± 21.53 0.425 
60 min pp 51.79 ± 29.82 67.53 ± 50.98 0.135 
120 min pp 26.84 ± 29.14 25.80 ± 28.88 0.851 
Serum C-peptide (nmol/L) 
Fasting 0.71 ± 0.27 0.79 ± 0.51 0.382 
60 min pp 2.21 ± 0.68 2.63 ± 1.20 0.060 
120 min pp 1.52 ± 0.85 1.53 ± 0.79 0.897 
VPA (µg/ml), fasting n.a 112.1 ± 25.7 n.a 
VPA (µg/ml), 60 min pp n.a 86.0 ± 20.9 n.a 
VPA (µg/ml), 120 min pp n.a 77.2 ± 19.3 n.a 




5.7. The effect of chronic valproate treatment  
on peripheral blood gene expression 
Gene expression profiles of blood RNA samples isolated from patients with 
epilepsy before and three months after the start of VPA treatment slightly 
differed. Eleven of the 23,099 analyzed genes showed statistically significant 
differential expression with multiple testing-adjusted false discovery rate values 
less than 0.1 (Table 10). Relative differences in the expression signal (fold 
change or log fold change) between two time points were generally low. After 
initiation of VPA treatment, only 2 genes were up-regulated more than 1.1 fold, 
and no genes were down-regulated more than 1.1 fold, compared to the status 
before VPA treatment. 
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Table 10. Most significantly up- or down-regulated genes after exposure to valproate. 
Gene 
symbol 
Log(FC) P FDR Gene name 
TPT1 –0.14 2.00 × 10–8 0.0004611 
Tumor protein, translationally 
controlled 1 
HBG2 0.86 3.16 × 10–7 0.0036545 Hemoglobin, gamma G 
ARAP3 0.51 6.32 × 10–7 0.0037739 
ArfGAP with RhoGAP domain, 
ankyrin repeat and PH domain 3 
RBM43 –0.58 6.54 × 10–7 0.0037739 RNA-binding motif protein 43 
ALAS2 0.72 9.99 × 10–7 0.0046131 Aminolevulinate, delta-, synthase 2 
MOSC1 0.58 4.61 × 10–6 0.0177665 
Mitochondrial amidoxime reducing 
component 1 
KLHDC8B 0.68 1.08 × 10–5 0.0356676 Kelch domain containing 8B 
SNORD89 –0.31 1.73 × 10–5 0.0498153 Small nucleolar RNA, C/D box 89 
PELI3 0.80 2.14 × 10–5 0.0550179 
Pellino E3 ubiquitin protein ligase 
family member 3 
TMEM150C 2.09 3.84 × 10–5 0.0887540 Transmembrane protein 150C 
C10orf25 1.12 4.55 × 10–5 0.0954488 
Chromosome 10 open reading 
frame 25 
FDR, false discovery rate. 
 
Functional annotation of expression profiles was subsequently applied to 
identify functional changes in the context of genetic networks. A dataset 
containing 11 genes with significant differential expression between before and 
after initiation of VPA treatment was uploaded into the Ingenuity Pathway 
Analysis software program. Only one genetic network was identified (enrich-
ment score = 30), which included genes related to cardiovascular system develop-
ment and function, cell morphology, as well as hematological system develop-
ment and function (Table 11, Figure 8). 
 
Table 11. Network of genes significantly changed after treatment with valproic acid. 
Molecules in network Score Focus molecules Top functions 
ABCB6, ACO1, ALAS2, ARAP3, 
BNIP3L, C10orf25, ETV6, GRB2, 
GSTP1, HBB, Hbb-b1, HBE1, HBG2, 
HBZ, IRAK2, IREB2, KLF1, 
KLHDC8B, MARC1, miR-3677-3p 
(miRNAs w/seed UCGUGGG),  
miR-4651 (and other miRNAs w/seed 
GGGGUGG), MTA1, NR2C1, PELI3, 
PER1, PER2, RBM43, RCOR1, 
SMAD5, SP1, SUCLA2, 













A network including the gene functions “cardiovascular system development and 
function,” “cell morphology,” and “hematological system development and 
function” was significantly enriched in patients with epilepsy after initiation of 
treatment with valproic acid (score = –log(p-value) = 30). Red nodes designate 
upregulated genes. Numbers indicate the log2 fold change (0 is equal expres-
sion). Uncolored nodes are genes in this network that were on our list of dif-
ferentially expressed genes. 
 
 
Figure 8. Annotation enrichment analysis.  
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6. DISCUSSION 
6.1. Comparison of the metabolic syndrome risk  
in valproate-treated patients with epilepsy and  
the general population 
For the first time, we demonstrated that the prevalence of MS in adult patients 
with epilepsy who received VPA treatment was 25.8%, which did not differ 
from the results of a population-based study (Eglit et al., 2012). Because subjects 
in both cohorts were drawn from the same population over the same extended 
time period, probably differences in genetic background and nutritional habits 
were minimal, which makes the results even more reliable. 
The tendency of patients with epilepsy on long-term VPA treatment to be 
overweight is generally recognized in the medical community (Stephen et al., 
2001). However, most studies examining weight gain and abdominal obesity 
during VPA treatment have been incident studies (Biton et al., 2003; Biton et 
al., 2001; Dinesen et al., 1984; Prabhakar et al., 2007; Privitera et al., 2003), 
that have used selected control subjects for comparison (only males or females) 
(de Vries et al., 2007; Isojarvi et al., 1996; Morrell et al., 2003; Prabhakar et al., 
2007; Pylvanen et al., 2003) or have not used controls at all (Dinesen et al., 
1984; El-Khatib et al., 2007; Prabhakar et al., 2007). Our results show that BMI 
is not higher in these patients than in the general population. Our study design is 
one of the main reasons for these results, as patients whose VPA treatment was 
discontinued due to side effects were not included in our cohort. This design 
likely resulted in negative selection bias against VPA-related side effects, such 
as weight gain. Nevertheless, the study reflects the true clinical practice of 
medical VPA usage and the management of VPA-related side effects in patients 
with epilepsy. Several studies reported that VPA-treated patients exhibited 
hyperinsulinemia and a tendency toward lower plasma glucose levels (reviewed 
by (Verrotti et al., 2009)), findings that were confirmed by our results. The 
observation of these changes in both obese and normal-weight patients suggests 
that hyperinsulinemia is the leading factor for weight gain and MS development 
during VPA treatment (Pylvanen et al., 2006a). 
Lipid metabolism findings in VPA-treated patients have been inconsistent. 
Some studies have associated VPA treatment with decreased HDL-C (Pylvanen 
et al., 2006b) and increased TG (Luef et al., 2002a; Pylvanen et al., 2006b; 
Stephen et al., 2001) levels, whereas others have found no effect of VPA treat-
ment on lipid metabolism (Fang et al., 2012; Pylvanen et al., 2003). One possible 
explanation is that VPA has no direct influence on TG or HDL-C metabolism, 
in contrast to its effect on insulin. Thus, the unfavorable changes in lipid levels 
probably occur during the development of MS, the prevalence of which was not 
increased among VPA-treated patients in our study. The diversity of previously 
reported data on changes in lipid levels during VPA treatment is probably 
related to differences in the subject selection methods. Specifically, the lipid 
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profiles are probably more unfavorable in cohorts with higher proportions of 
VPA-treated patients with MS. 
Previous studies have paid little attention to the important side effects of 
prolonged VPA treatment, such as a tendency towards elevated BP (Fang et al., 
2012; Pylvanen et al., 2006b). This characteristic can be explained by the in-
creased serum insulin levels in VPA-treated patients, which can lead to elevated 
sympathetic activity (Gallagher et al., 2010). The increased proportion of VPA-
treated patients with high BP, in the absence of differences in the prevalence of 
other MS components, suggests that the tendency towards hypertension is a 
direct effect of VPA treatment, probably due to hyperinsulinemia. Although MS 
did not occur more frequently in our VPA-treated patients, the risks of cardio-
vascular and cerebrovascular diseases may be increased, given than hyper-
tension is the leading cause of these conditions.  
The pathophysiology of MS remains unclear, but many of its features are 
associated with IR, which is typically defined as decreased sensitivity or 
responsiveness to the metabolic action of insulin (Chiang et al., 2011). The gold 
standard method for assessment of IR is the hyperinsulinemic-euglycemic 
clamp technique originally developed by DeFronzo et al. (DeFronzo et al., 
1979). As this method is complex and unsuitable for epidemiological investiga-
tions, several surrogate indices, such as the HOMA-IR index, have been 
developed.  
Previous studies using the HOMA-IR index have reported the presence of IR 
in patients receiving VPA treatment (Fang et al., 2012; Luef et al., 2002a; 
Pylvanen et al., 2003; Verrotti et al., 2011b; Verrotti et al., 2009). However, an 
increased HOMA-IR index in these patients most likely reflects hyper-
insulinemia, which can occur in obese and normal-weight patients. Pylvänen et 
al. (Pylvanen et al., 2006a) first raised this issue and suggested that VPA inter-
feres with insulin degradation in the liver, resulting in higher insulin con-
centrations in the peripheral circulation. In this case, an increased HOMA value 
probably does not reflect reduced sensitivity to insulin. Indeed, we found 
significantly higher HOMA indices in VPA-treated patients than in control 
subjects, although the prevalence of MS was similar in both cohorts. ROC 
analyses of the predictive abilities of BMI and HOMA-IR for MS suggested that 
HOMA-IR was an inferior predictor of MS in VPA-treated patients compared to 
the general population. These results allow us to speculate that previous studies 
applying the HOMA-IR index in VPA-treated patients have probably overes-
timated the occurrence of IR. 
 
 
6.2. Comparison of risk factors for metabolic syndrome in 
epilepsy patients treated with valproate or carbamazepine 
The primary aim of this part of study was to determine whether treatment with 
either of the two most frequently used AEDs is correlated with the risk of MS 
and its components in patients with epilepsy. We identified all patients from 
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selected southern Estonia counties who were prescribed with VPA or CBZ. The 
final sample included 213 persons with epilepsy treated with VPA or CBZ 
monotherapy. The risk of MS appeared to be similar in both groups. However, 
due to the limitations of the cross-sectional study design, we did not have data 
on body weight or MS prevalence before the start of AED treatment. Moreover, 
many patients had been diagnosed with epilepsy for decades, and we were 
unable to collect data from all patients concerning their previously used AEDs 
and AED dosages, because old medical documentation was missing. Therefore, 
whether treatment with VPA or CBZ directly influences the risk of MS could 
not be ascertained. Females on VPA treatment had a higher risk of MS compared 
to males, although this difference was not statistically significant. Similarly, 
Kim and Lee reported that women with epilepsy on VPA monotherapy more 
frequently suffer from MS compared to women treated with CBZ, LTG, or 
TPM (Kim and Lee, 2007). In our study, two MS components (increased waist 
circumference and decreased HDL-C concentration) were more frequently 
observed in VPA-treated females compared to males. 
In the initial study population, a significantly higher number of CBZ- 
compared to VPA-treated patients had severe physical or mental disability due 
to brain damage and were excluded from the final sample. This difference 
between patients treated with different AEDs can be explained by the fact that 
CBZ is the first-line AED for focal seizures, which are frequently caused by 
focal brain damage of different etiologies (Schmidt and Schachter, 2014). 
Although the etiology of epilepsy differed between the treatment groups, we did 
not find a significant correlation between the risk of MS and epilepsy etiology. 
A very consistent finding across different populations is that the prevalence 
of MS is highly age-dependent (Eckel et al., 2005). For example, in an Estonian 
population, the prevalence of MS was determined to be 19% in the 20- to 44-
year-old age group compared to 45% in the 61- to 74-year-old age group (Eglit 
et al., 2012). In our sample, age was the only significant risk factor for MS in 
patients with epilepsy. This result is probably a reflection of the global trend.  
Our study showed that the presence of MS was associated with higher VPA 
doses, with borderline statistical significance (P = 0.075), and was not associated 
with CBZ doses. Consistent with our result, Fang et al. reported a similar 
association between higher VPA doses and MS (P = 0.049) (Fang et al., 2012). 
Another study in children reported a significant correlation between the daily 
administered VPA dose and insulin resistance, which is one of the main signs of 
MS (Masuccio et al., 2010). A long duration of VPA therapy tended to increase 
the risk of MS, which is consistent with previous reports showing a positive 
correlation between VPA treatment duration and significant weight gain 
(Verrotti et al., 2011b). 
We found no difference in BMI between VPA- and CBZ-treated subjects, 
which could be explained by the similar effect of both drugs on weight and by 
the prevalence design of our study. Patients whose VPA or CBZ treatment was 
discontinued due to side effects were not included in our cohort.  
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The real pathogenic mechanism underlying VPA-induced weight gain is un-
known, although many authors believe that IR may play a central role. It is not 
clear, however, whether this IR is a result of weight gain, or whether VPA 
treatment itself can directly cause hyperinsulinemia and IR (Belcastro et al., 
2013). Increasing evidence suggests that VPA treatment is associated with 
lower blood glucose concentration, a finding that is not consistent with the 
reduced insulin sensitivity hypothesis (Demir and Aysun, 2000; Pylvanen et al., 
2006a; Terasmaa et al., 2011). In our study, patients on VPA treatment had lower 
fasting blood glucose concentrations, with borderline significance. These findings 
argue against the presence of increased IR among these patients. One possible 
mechanism to explain the weight gain in VPA-treated patients could be that the 
VPA-mediated decrease in glucose levels stimulates the appetite, leading to 
obesity and, probably, increased IR (El-Khatib et al., 2007; Farinelli et al., 2015). 
Patients treated with CBZ had significantly higher HDL-C concentrations. 
This effect was especially pronounced in women. TG levels also tended to be 
higher in this patient group, although without reaching the level of statistical 
significance. The lipid-increasing effect of CBZ has been described in the 
medical literature, as recently reviewed by Katsiki et al. (Katsiki et al., 2014) 
and Vyas et al (Vyas et al., 2015). CBZ is a well-known enhancer of the hepatic 
cytochrome P450 enzyme system, which is extensively involved in the syn-
thesis and metabolism of cholesterol. In contrast, VPA is an enzyme inhibitor 
and exerts the opposite action from CBZ (Nebert and Russell, 2002). CBZ 
monotherapy has been associated with increases in total cholesterol, low-density 
lipoprotein cholesterol, HDL-C, and TG concentrations (Katsiki et al., 2014; 
Luef et al., 2002a). Interestingly, the observed gender effect of CBZ on HDL-C 
was also reported by others (Sudhop et al., 1999).  
Although the enzyme-inducing effect of CBZ undoubtedly causes dys-
lipidemia in patients treated with this drug, the increased concentrations of some 
lipid fractions, especially HDL-C, could potentially have a protective effect 
against MS. Indeed, in our study, the presence of a pathologically low plasma 
HDL-C concentration was significantly less frequent in CBZ-treated patients. 
This trend probably decreased the overall prevalence of MS in this group. 
However, in populations of patients who use lipid metabolism-modifying drugs, 
such as CBZ, the MS diagnostic criteria should be applied with caution, con-
sidering the direct effects of such drugs on these criteria. 
 
 
6.3. The effect of acute intravenous valproate-treatment 
on the glucose, insulin and C-peptide metabolism 
In the third part of the study, to evaluate the effect of VPA on glucose and 
insulin metabolism in naive patients with newly diagnosed epilepsy several 
parameters were measured. Our findings show, for the first time, that VPA 
administration appears to decrease glucose levels during OGTT directly fol-
lowing the initial VPA exposure. This is consistent with previous studies on 
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animal models, which have suggested that VPA may influence blood glucose 
concentration. Turnbull et al. showed that VPA causes a moderate fall in blood 
glucose levels following either oral or intraperitoneal administration in Wistar 
rats (Turnbull et al., 1985). Recently, Terasmaa et al. also showed that acute 
VPA administration lowers blood glucose levels in streptozocin-induced type 1 
diabetic mice, in the absence of insulin (Terasmaa et al., 2011). In our study, 
decreased glucose levels during OGTT following VPA administration occurred 
without significant changes in insulin and C-peptide concentrations, consistent 
with the idea that an insulin-independent mechanism may be involved. Evi-
dence for the central regulation of glucose homeostasis has been accumulating 
from both animal and human studies. Hypothalamic ATP-sensitive potassium 
(KATP) channels have been shown to play a significant role in the central regu-
lation of glucose homeostasis; activation of KATP channels within the medial 
hypothalamus is sufficient to decrease blood glucose levels via the suppression 
of glucose production (Pocai et al., 2005). Recently, it has been shown in vitro, 
that exposure to VPA modulates the activity of KATP channels (Manaka et al., 
2014). Further investigations are needed to explore the possible relationship 
between KATP channel activity and the metabolic changes that result from VPA 
treatment. 
Another possibility is that VPA itself has a direct effect upon the control of 
endogenous glucose production by the central nervous system. VPA is a 
branched chain fatty acid and thus, with VPA administration, plasma levels of 
FFAs, which are key modulators of endogenous glucose production, could in-
crease (Luef et al., 2002b). The hypothalamus has been shown to sense 
circulating levels of nutrients, which include fatty acids, and to accordingly 
regulate food intake and whole-body glucose handling (Schwartz et al., 2000). 
For example, intracerebroventricular infusion of the long-chain fatty acid, oleic 
acid, in rats caused rapid reductions in food intake and inhibits endogenous 
glucose production (Obici et al., 2002).  
Investigators in the field have debated whether metabolic changes that occur 
during VPA treatment are directly caused by VPA, or are simply the con-
sequence of weight gain, which is a frequent side effect of the drug (Belcastro et 
al., 2013). Our findings are consistent with previous reports (Luef et al., 2003; 
Pylvanen et al., 2006a) that support the first idea, namely, a direct impact of 
VPA upon glucose metabolism. In this case, decrease in blood glucose level 
that results from VPA treatment may stimulate appetite, thereby increasing food 
intake that results in weight gain. Correspondingly, in a study conducted by El-
Khatib et al., VPA treatment was associated with a high frequency of carbo-
hydrate cravings, especially in women with epilepsy, and this led to weight gain 
(El-Khatib et al., 2007). 
VPA is a potent inhibitor of HDAC enzymes; VPA treatment promotes 
histone acetylation, leading to the relaxation of the chromatin and facilitating 
transcriptional activation. HDAC inhibitors were recently shown to be prom-
ising for the treatment of diabetes mellitus. Administration of these compounds 
can promote pancreatic β-cell development, proliferation, differentiation and 
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function, and ameliorate microvascular complications in later stages of the 
disease (Christensen et al., 2011). The acute moderate hypoglycemic effect of 
IV VPA that was observed in the current study is likely too rapid to be mediated 
via HDAC inhibition. This effect, however, could serve as motivation for future 
preclinical and clinical trials to test the utility of HDAC inhibitors, and especially 
VPA, as a potential novel therapy for diabetes. In fact, VPA has been used for 
years in diabetes patients to treat neuropathic pain. According to the guidelines 
for the treatment of diabetic peripheral neuropathy, developed by the American 
Academy of Neurology, VPA may be effective and should be considered for the 
treatment of diabetic polyneuropathy (Bril et al., 2011). The results of our study 
suggest that VPA could be used more widely in selected patients with diabetes. 
 
 
6.4. The effect of chronic valproate-treatment  
on peripheral blood gene expression 
In the last part of study, we examined VPA-induced changes in gene expression 
in the peripheral blood of patients with newly diagnosed epilepsy who were 
treated with therapeutic doses of the drug.  
More than a decade ago, VPA was identified as a potent promotor of histone 
acetylation. Histone acetylation leads to relaxation of the nucleosome structure 
and transcriptional activation (Gottlicher et al., 2001). In theory, HDAC inhibition 
could directly or indirectly affect between 2% and 5% of all genes (Van Lint et 
al., 1996). In mouse embryonic stem cells exposed to VPA, the expression levels 
of 2.4% of genes were altered by more than 1.5 fold (Boudadi et al., 2013). This 
property of VPA is believed to have an impact on embryogenesis (Phiel et al., 
2001), causing increased rates of major congenital malformations among children 
exposed to this drug in utero (Tomson and Battino, 2012). Only one study has 
compared the genomic expression patterns in peripheral blood between epilepsy 
patients treated with VPA or without any drug. Expression levels of 461 genes 
were altered in VPA-treated compared to drug-free epilepsy patients; however, 
no information was provided regarding the VPA doses that were used (Tang et 
al., 2004). 
Although we did not measure VPA-induced HDAC inhibition, the finding 
that a surprisingly small number of genes were differently expressed before and 
after the start of VPA treatment suggests that HDAC inhibition in our patients 
was very low or even absent. In vitro, HDAC inhibition is achieved at con-
centrations of 0.3 to 1.0 mM, corresponding to the serum drug concentration in 
patients treated with a daily dose of 20 to 30 mg/kg (Gottlicher et al., 2001). 
According to the guidelines of epilepsy treatment in adults (Schmidt and 
Schachter, 2014), we initiated VPA treatment in our patients at a minimal 
effective dose, with the mean daily dose of 11.4 ± 2.8 mg/kg. The lack of the 
HDAC inhibition in our study is probably related to the relatively low daily 
VPA dose that was used. Indeed, the risk of major congenital malformations in 
patients treated with VPA increases with doses above 700 mg/d and is 
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pronounced with doses above 1500 mg/d (Tomson and Battino, 2012), which 
are clearly higher than the doses used in our study (600–1200 mg/d). 
During the evaluation period of about 3 months, no patient reported any 
epileptic seizures. However, the small sample size and short evaluation period 
prohibit us from making conclusions about whether seizure freedom was related 
to the VPA treatment or to the natural course of disease. Most patients had a 
presumed genetic etiology for their epilepsy, which usually suggests a self-
limiting course. The anticonvulsive effect of VPA is mediated mainly through 
the reduced degradation, increased synthesis, decreased turnover, and, therefore, 
reduced activity of gamma amino butyrate, and is probably not related to the 
alteration of gene expression (Chateauvieux et al., 2010). We could speculate 
that the anticonvulsive effect of VPA in our study was achieved without 
significant general activation of transcriptional activity. 
After exposure to VPA, we observed changes in the expression levels of 
several genes (TPT1, ARAP3, and KLHDC8B) that are reported to be important 
in cancer-related pathways (Kobayashi et al., 2014; Krem et al., 2012; Yagi et 
al., 2011). Furthermore, the expression levels of two genes related to mito-
chondrial function, MOSC1 and ALAS2, were significantly changed. The 
product of MOSC1 localizes to the outer mitochondrial membrane and con-
tributes to the regulation of nitric oxide synthesis (Klein et al., 2012). ALAS2 is 
an erythroid-specific, mitochondrially located enzyme that participates in heme 
biosynthetic pathways (Fujiwara and Harigae, 2013). Among the antiepileptic 
drugs, VPA has the highest potential to induce mitochondrial toxicity and could 
be even fatal in patients with some mitochondrial diseases. Use of VPA could 
be associated with the inhibition of respiratory chain complexes, impaired struc-
tural organization, and altered potential of the inner mitochondrial membrane 
(Nanau and Neuman, 2013; Pourahmad et al., 2012). Further investigations are 
needed to determine whether the differentially expressed genes identified in our 
study play roles in VPA-related mitochondrial toxicity. 
 
 
6.5. Strengths and limitations of the study 
Strengths of the two first parts of the study include the population-based design 
and the relatively large cohort size compared to other published studies 
investigating MS risk in patients with epilepsy.  
The major limitation of the first part of the study was that patients with 
epilepsy on VPA treatment were compared to subjects without epilepsy. In people 
with epilepsy, a sedentary lifestyle and decreased level of physical activity due 
to epilepsy itself are related to the risk of obesity and metabolic disturbances 
(Ben-Menachem, 2007; Steinhoff et al., 1996). In addition, the comorbidity 
profile differs between patients with epilepsy and healthy subjects, as described 
above.  
To overcome these limitations, only patients with epilepsy treated with 
different anticonvulsants were studied in the second part of this research. 
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Nevertheless, the heterogeneity of patients treated with VPA or CBZ was a 
major confounding factor in the second part. One of the most important 
determinants of MS, patient age, differed between the cohorts. VPA-treated 
patients were younger than CBZ-treated patients. VPA is used mainly for the 
treatment of generalized epilepsies, which usually manifest in children and 
young adults. For the same reason, the epilepsy etiology was different between 
the two groups, which could have an effect on MS risk. Moreover, our study 
may have underestimated the effect of the epileptic syndrome on MS risk. It 
was difficult to differentiate the potential effect of VPA from the effect of gene-
ralized epilepsy on MS risk, as almost no patients with generalized epilepsy 
were treated with CBZ. Physical activity level and diet, as important MS risk 
factors, were not assessed, constituting another limitation. Lack of information 
on patient weight and MS status before treatment, as well as partially missing 
data on previously used AEDs, prevented us from making conclusions about the 
causal relationships of the studied AEDs and MS. In addition, a substantial 
proportion of patients from the initial drug prescription database refused to 
participate or had incorrect or missing contact information. Considering these 
limitations, the results of this study should be interpreted carefully. Given that 
the study design focused on prevalence, the findings cannot be used to indicate 
whether VPA or CBZ causes weight gain. Nevertheless, we observed that 
patients with epilepsy who received VPA or CBZ treatment were not more 
overweight than other people in our population. 
One of the limitations of the third part of the study was the relatively small 
sample size. However, the paired design of the study allowed us to minimize the 
influence of external factors and discover significant changes. Another limi-
tation was that we used IV administration of relatively high doses of VPA, an 
approach that is not common in clinical practice. In addition, blood glucose 
levels were not measured after prolonged use of VPA. Consequently, no data 
are available regarding the long-term effects of VPA treatment on glucose 
metabolism. Future studies should include a wider range of ages, including 
children, and should be designed to evaluate the long-term effects of 
administering lower doses of VPA orally on glucose metabolism. 
The relatively small sample size of patients was also a limitation of the 
fourth part of the study. The relatively low VPA dose received by study parti-
cipants leaves open the possibility that the expressions of many genes were not 
influenced. On the other hand, the results probably reflect the gene expression 
profile in a real clinical practice, with relatively low doses of VPA. Another 
important limitation was the absence of relevant clinical problems in our 
patients, besides epilepsy. It was not possible for us to correlate changes in gene 




6. . Practical implications and future perspectives 
The current study does not show increased general risk of MS in patients treated 
with VPA, CBZ, or control subjects. Due to sex differences, from a practical 
point of view, these results suggest that in females with a higher risk of cardio-
vascular diseases, AEDs other than VPA could be considered first. Treatment 
with either VPA or CBZ in males probably does not correlate with different MS 
risk in the future. The association of MS with higher VPA doses suggests that 
the lowest effective dose should be used, to minimize the possibility of MS in 
VPA-treated patients.  
The general opinion in the medical community is that patients with epilepsy 
who receive long-term VPA treatment gain weight. However, due to the paucity 
of well-controlled prospective trials, the real incidence and magnitude of this 
problem are unknown (Verrotti et al., 2011b). Recently published meta-analyses 
have confirmed that, in general, overweight and obesity are associated with 
higher all-cause mortality (Global, 2016). The overall mortality rate among 
people with epilepsy already is increased due to epilepsy-related comorbidities 
and sudden unexpected death syndrome (Moshe et al., 2015). Since VPA is 
used by millions of people worldwide, double-blind, prospective, controlled 
clinical trials are needed to determine the real incidence of weight increase in 
these patients.  
The direct hypoglycemic effect of VPA has remained largely unnoticed in 
the medical literature, but it could be one of the main molecular mechanisms of 
weight gain in VPA-treated patients. It would be interesting to examine whether 
VPA has long-term effects on glucose metabolism. For example, would a lower 
glucose concentration during the OGTT after acute IV administration of VPA 
lead to a higher risk of future weight gain? If so, then the results of OGTT could 
serve as a biomarker for predicting the risk of an important side effect in patients 
with newly diagnosed epilepsy in whom VPA treatment is planned. Which 
genetic factors are important for mediating the effects of VPA on glucose meta-
bolism? Further preclinical and clinical studies are needed to investigate the 
exact mechanism of the hypoglycemic effect of VPA and to test the utility of 
HDAC inhibitors, especially VPA, as potential novel therapies for diabetes. 
Regarding the part of the study examining VPA-induced gene expression, 
the results suggest that the lowest effective dose of VPA should be used, to avoid 
side effects of HDAC inhibition. Future studies should explore whether the use 
of higher VPA blood concentrations (e.g., VPA doses > 1500 mg/d) signi-
ficantly changes the gene expression profile. In this case, due to ethical issues, a 
different study design should be used, probably comparing gene expression in 
independent samples, such as patients treated with high VPA doses compared to 





1. The prevalence of MS in adult patients with epilepsy who received VPA 
monotherapy was 25.8%, which was not different from the prevalence of MS 
in the Estonian population (OR = 1.00; 95% CI, 0.59–1.68). However, VPA-
treated patients had higher serum insulin concentrations, independent of 
body mass index. This finding suggests that hyperinsulinemia is not a con-
sequence of obesity, but probably a direct effect of VPA treatment. HOMA-IR 
had a lower predictive ability for MS in patients who received VPA treat-
ment compared to the general population, probably suggesting that this index 
is not suitable to assess IR in VPA-treated patients.  
2. The general risk of MS was similar between adult patients with epilepsy who 
were treated with VPA or CBZ monotherapy. However, the distribution of 
MS components in these patients was different. Patients on CBZ treatment 
less frequently had decreased HDL-C levels, whereas patients on VPA treat-
ment less frequently had increased blood glucose levels. Females on VPA 
treatment could be at higher risk of MS than males. 
3. VPA administration decreased glucose levels during OGTT directly fol-
lowing the initial VPA exposure in patients with newly diagnosed epilepsy. 
This effect occurred without significant changes in insulin and C-peptide 
concentrations, suggesting that an insulin-independent mechanism may be 
involved. Glucose-lowering effect of VPA may stimulate appetite, which 
could result in weight gain. 
4. At low therapeutic dosages, VPA modulated the expression of a surprisingly 
small number of genes. Therefore, to avoid potential side effects of HDAC 





Adab, N., Kini, U., Vinten, J., Ayres, J., Baker, G., Clayton-Smith, J., Coyle, H., Fryer, 
A., Gorry, J., Gregg, J., Mawer, G., Nicolaides, P., Pickering, L., Tunnicliffe, L., 
Chadwick, D.W., 2004. The longer term outcome of children born to mothers with 
epilepsy. J. Neurol. Neurosurg. Psychiatry 75, 1575–1583. 
Akindele, A.J., Otuguor, E., Singh, D., Ota, D., Benebo, A.S., 2015. Hypoglycemic, 
antilipidemic and antioxidant effects of valproic acid in alloxan-induced diabetic 
rats. Eur. J. Pharmacol. 762, 174–183. 
Anderson, G.D., 2002. Children versus adults: pharmacokinetic and adverse-effect dif-
ferences. Epilepsia 43 Suppl 3, 53–59. 
Anderson, G.D., Lin, Y.X., Berge, C., Ojemann, G.A., 1997. Absence of bleeding 
complications in patients undergoing cortical surgery while receiving valproate 
treatment. J. Neurosurg. 87, 252–256. 
Anderson, G.D., Temkin, N.R., Chandler, W.L., Winn, H.R., 2003. Effect of valproate 
on hemostatic function in patients with traumatic brain injury. Epilepsy Res. 57, 
111–119. 
Aydin, K., Serdaroglu, A., Okuyaz, C., Bideci, A., Gucuyener, K., 2005. Serum insulin, 
leptin, and neuropeptide y levels in epileptic children treated with valproate. J. Child 
Neurol. 20, 848–851. 
Bauer, J., Jarre, A., Klingmuller, D., Elger, C.E., 2000. Polycystic ovary syndrome in 
patients with focal epilepsy: a study in 93 women. Epilepsy Res. 41, 163–167. 
Belcastro, V., D’Egidio, C., Striano, P., Verrotti, A., 2013. Metabolic and endocrine 
effects of valproic acid chronic treatment. Epilepsy Res. 107, 1–8. 
Ben-Menachem, E., 2007. Weight issues for people with epilepsy – a review. Epilepsia 
48 Suppl 9, 42–45. 
Berg, A.T., Berkovic, S.F., Brodie, M.J., Buchhalter, J., Cross, J.H., van Emde Boas, 
W., Engel, J., French, J., Glauser, T.A., Mathern, G.W., Moshe, S.L., Nordli, D., 
Plouin, P., Scheffer, I.E., 2010. Revised terminology and concepts for organization 
of seizures and epilepsies: report of the ILAE Commission on Classification and 
Terminology, 2005–2009. Epilepsia 51, 676–685. 
Bilo, L., Meo, R., 2006. Epilepsy and polycystic ovary syndrome: where is the link? 
Neurol. Sci. 27, 221–230. 
Bilo, L., Meo, R., Nappi, C., Annunziato, L., Striano, S., Colao, A.M., Merola, B., Bus-
caino, G.A., 1988. Reproductive endocrine disorders in women with primary 
generalized epilepsy. Epilepsia 29, 612–619. 
Biton, V., Levisohn, P., Hoyler, S., Vuong, A., Hammer, A.E., 2003. Lamotrigine 
versus valproate monotherapy-associated weight change in adolescents with epi-
lepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J. 
Child Neurol. 18, 133–139. 
Biton, V., Mirza, W., Montouris, G., Vuong, A., Hammer, A.E., Barrett, P.S., 2001. 
Weight change associated with valproate and lamotrigine monotherapy in patients 
with epilepsy. Neurology 56, 172–177. 
Boudadi, E., Stower, H., Halsall, J.A., Rutledge, C.E., Leeb, M., Wutz, A., O'Neill, 
L.P., Nightingale, K.P., Turner, B.M., 2013. The histone deacetylase inhibitor 
sodium valproate causes limited transcriptional change in mouse embryonic stem 
cells but selectively overrides Polycomb-mediated Hoxb silencing. Epigenetics 
Chromatin 6, 11. 
59 
Brainin, M., Barnes, M., Baron, J.C., Gilhus, N.E., Hughes, R., Selmaj, K., Waldemar, 
G., 2004. Guidance for the preparation of neurological management guidelines by 
EFNS scientific task forces – revised recommendations 2004. Eur. J. Neurol. 11, 
577–581. 
Bril, V., England, J., Franklin, G.M., Backonja, M., Cohen, J., Del Toro, D., Feld-
man, E., Iverson, D.J., Perkins, B., Russell, J.W., Zochodne, D., 2011. Evidence-
based guideline: Treatment of painful diabetic neuropathy: report of the American 
Academy of Neurology, the American Association of Neuromuscular and Electro-
diagnostic Medicine, and the American Academy of Physical Medicine and Rehabi-
litation. PM R 3, 345–352, 352 e341–321. 
Brown, R., Imran, S.A., Ur, E., Wilkinson, M., 2008. Valproic acid and CEBPalpha-
mediated regulation of adipokine gene expression in hypothalamic neurons and 3T3-
L1 adipocytes. Neuroendocrinology 88, 25–34. 
Brusilow, S.W., 2002. Hyperammonemic encephalopathy. Medicine (Baltimore) 81, 
240–249. 
Bryant, A.E., 3rd, Dreifuss, F.E., 1996. Valproic acid hepatic fatalities. III. U.S. expe-
rience since 1986. Neurology 46, 465–469. 
Burton, B.S., 1882. On the propyl derivatives and decomposition products of ethyl-
acetoacetate. Am Chem J, 385–395. 
Campbell, E., Kennedy, F., Russell, A., Smithson, W.H., Parsons, L., Morrison, P.J., 
Liggan, B., Irwin, B., Delanty, N., Hunt, S.J., Craig, J., Morrow, J., 2014. 
Malformation risks of antiepileptic drug monotherapies in pregnancy: updated 
results from the UK and Ireland Epilepsy and Pregnancy Registers. J. Neurol. 
Neurosurg. Psychiatry 85, 1029–1034. 
Cataldo, N.A., 1997. Insulin-like growth factor binding proteins: do they play a role in 
polycystic ovary syndrome? Semin. Reprod. Endocrinol. 15, 123–136. 
Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., Charlton, 
M., Sanyal, A.J., 2012. The diagnosis and management of non-alcoholic fatty liver 
disease: practice guideline by the American Gastroenterological Association, Ameri-
can Association for the Study of Liver Diseases, and American College of Gastro-
enterology. Gastroenterology 142, 1592–1609. 
Chateauvieux, S., Morceau, F., Dicato, M., Diederich, M., 2010. Molecular and thera-
peutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010. 
Chen, Y., Tsai, Y.H., Tseng, S.H., 2012. Valproic acid affected the survival and 
invasiveness of human glioma cells through diverse mechanisms. J. Neurooncol. 
109, 23–33. 
Chiang, J.K., Lai, N.S., Chang, J.K., Koo, M., 2011. Predicting insulin resistance using 
the triglyceride-to-high-density lipoprotein cholesterol ratio in Taiwanese adults. 
Cardiovasc. Diabetol. 10, 93. 
Christensen, D.P., Dahllof, M., Lundh, M., Rasmussen, D.N., Nielsen, M.D., Billestrup, 
N., Grunnet, L.G., Mandrup-Poulsen, T., 2011. Histone deacetylase (HDAC) inhi-
bition as a novel treatment for diabetes mellitus. Mol. Med. 17, 378–390. 
Davis, R., Peters, D.H., McTavish, D., 1994. Valproic acid. A reappraisal of its 
pharmacological properties and clinical efficacy in epilepsy. Drugs 47, 332–372. 
de Vries, L., Karasik, A., Landau, Z., Phillip, M., Kiviti, S., Goldberg-Stern, H., 2007. 
Endocrine effects of valproate in adolescent girls with epilepsy. Epilepsia 48, 470–
477. 
DeFronzo, R.A., Tobin, J.D., Andres, R., 1979. Glucose clamp technique: a method for 
quantifying insulin secretion and resistance. Am. J. Physiol. 237, E214–223. 
60 
Demir, E., Aysun, S., 2000. Weight gain associated with valproate in childhood. 
Pediatr. Neurol. 22, 361–364. 
Deutsch, S.I., Burket, J.A., Rosse, R.B., 2009. Valproate-induced hyperammonemic 
encephalopathy and normal liver functions: possible synergism with topiramate. 
Clin. Neuropharmacol. 32, 350–352. 
Dhir, A., Sharma, S., Jain, P., Bhakhri, B.K., Aneja, S., 2015. Parameters of metabolic 
syndrome in Indian children with epilepsy on valproate or phenytoin monotherapy. 
J. Pediatr. Neurosci. 10, 222–226. 
Dinesen, H., Gram, L., Andersen, T., Dam, M., 1984. Weight gain during treatment 
with valproate. Acta Neurol. Scand. 70, 65–69. 
Dreifuss, F.E., Langer, D.H., Moline, K.A., Maxwell, J.E., 1989. Valproic acid hepatic 
fatalities. II. US experience since 1984. Neurology 39, 201–207. 
Dreifuss, F.E., Santilli, N., Langer, D.H., Sweeney, K.P., Moline, K.A., Menander, K.B., 
1987. Valproic acid hepatic fatalities: a retrospective review. Neurology 37, 379–
385. 
Eckel, R.H., Grundy, S.M., Zimmet, P.Z., 2005. The metabolic syndrome. Lancet 365, 
1415–1428. 
Eglit, T., Rajasalu, T., Lember, M., 2012. Metabolic syndrome in estonia: prevalence 
and associations with insulin resistance. Int. J. Endocrinol. 2012, 951672. 
El-Khatib, F., Rauchenzauner, M., Lechleitner, M., Hoppichler, F., Naser, A., Wald-
mann, M., Trinka, E., Unterberger, I., Bauer, G., Luef, G.J., 2007. Valproate, weight 
gain and carbohydrate craving: a gender study. Seizure 16, 226–232. 
Evers, S., Afra, J., Frese, A., Goadsby, P.J., Linde, M., May, A., Sandor, P.S., 2009. 
EFNS guideline on the drug treatment of migraine – revised report of an EFNS task 
force. Eur. J. Neurol. 16, 968–981. 
Fang, J., Chen, S., Tong, N., Chen, L., An, D., Mu, J., Zhou, D., 2012. Metabolic 
syndrome among Chinese obese patients with epilepsy on sodium valproate. Seizure 
21, 578–582. 
Farinelli, E., Giampaoli, D., Cenciarini, A., Cercado, E., Verrotti, A., 2015. Valproic acid 
and nonalcoholic fatty liver disease: A possible association? World J. Hepatol. 7, 
1251–1257. 
Finsterer, J., Segall, L., 2010. Drugs interfering with mitochondrial disorders. Drug 
Chem. Toxicol. 33, 138–151. 
Finsterer, J., Zarrouk Mahjoub, S., 2012. Mitochondrial toxicity of antiepileptic drugs 
and their tolerability in mitochondrial disorders. Expert Opin. Drug Metab. Toxicol. 
8, 71–79. 
Fishbein, M.H., Mogren, C., Gleason, T., Stevens, W.R., 2006. Relationship of hepatic 
steatosis to adipose tissue distribution in pediatric nonalcoholic fatty liver disease. J. 
Pediatr. Gastroenterol. Nutr. 42, 83–88. 
Fu, J.F., Liang, L., Zou, C.C., Hong, F., Wang, C.L., Wang, X.M., Zhao, Z.Y., 2007. 
Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and 
adolescents and the effect of metformin combined with lifestyle intervention. Int. J. 
Obes. (Lond.) 31, 15–22. 
Fujiwara, T., Harigae, H., 2013. Pathophysiology and genetic mutations in congenital 
sideroblastic anemia. Pediatr. Int. 55, 675–679. 
Gaitatzis, A., Carroll, K., Majeed, A., J, W.S., 2004. The epidemiology of the 
comorbidity of epilepsy in the general population. Epilepsia 45, 1613–1622. 
Gallagher, E.J., Leroith, D., Karnieli, E., 2010. Insulin resistance in obesity as the 
underlying cause for the metabolic syndrome. Mt. Sinai J. Med. 77, 511–523. 
61 
Genton, P., Bauer, J., Duncan, S., Taylor, A.E., Balen, A.H., Eberle, A., Pedersen, B., 
Salas-Puig, X., Sauer, M.V., 2001. On the association between valproate and 
polycystic ovary syndrome. Epilepsia 42, 295–304. 
Ghodke-Puranik, Y., Thorn, C.F., Lamba, J.K., Leeder, J.S., Song, W., Birnbaum, A.K., 
Altman, R.B., Klein, T.E., 2013. Valproic acid pathway: pharmacokinetics and 
pharmacodynamics. Pharmacogenet. Genomics 23, 236–241. 
Glauser, T., Ben-Menachem, E., Bourgeois, B., Cnaan, A., Guerreiro, C., Kalviainen, R., 
Mattson, R., French, J.A., Perucca, E., Tomson, T., 2013. Updated ILAE evidence 
review of antiepileptic drug efficacy and effectiveness as initial monotherapy for 
epileptic seizures and syndromes. Epilepsia 54, 551–563. 
Global, B.M.I.M.C., 2016. Body-mass index and all-cause mortality: individual-
participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 
Gomez, M.R., 1981. Possible teratogenicity of valproic acid. J. Pediatr. 98, 508–509. 
Gottlicher, M., Minucci, S., Zhu, P., Kramer, O.H., Schimpf, A., Giavara, S., Sleeman, 
J.P., Lo Coco, F., Nervi, C., Pelicci, P.G., Heinzel, T., 2001. Valproic acid defines a 
novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO 
J. 20, 6969–6978. 
Greco, R., Latini, G., Chiarelli, F., Iannetti, P., Verrotti, A., 2005. Leptin, ghrelin, and 
adiponectin in epileptic patients treated with valproic acid. Neurology 65, 1808–
1809. 
Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.A., Eckel, R.H., Franklin, B.A., 
Gordon, D.J., Krauss, R.M., Savage, P.J., Smith Jr, S.C., Spertus, J.A., Costa, F., 
2005. Diagnosis and management of the metabolic syndrome. An American Heart 
Association/National Heart, Lung, and Blood Institute Scientific Statement. 
Executive summary. Cardiol. Rev. 13, 322–327. 
Hamed, S.A., Fida, N.M., Hamed, E.A., 2009. States of serum leptin and insulin in 
children with epilepsy: risk predictors of weight gain. Eur. J. Paediatr. Neurol. 13, 
261–268. 
Hamilton-Fairley, D., Kiddy, D., Anyaoku, V., Koistinen, R., Seppala, M., Franks, S., 
1993. Response of sex hormone binding globulin and insulin-like growth factor 
binding protein-1 to an oral glucose tolerance test in obese women with polycystic 
ovary syndrome before and after calorie restriction. Clin. Endocrinol. (Oxf.) 39, 
363–367. 
Hernandez-Diaz, S., Smith, C.R., Shen, A., Mittendorf, R., Hauser, W.A., Yerby, M., 
Holmes, L.B., 2012. Comparative safety of antiepileptic drugs during pregnancy. 
Neurology 78, 1692–1699. 
Hill, J.O., Wyatt, H.R., Peters, J.C., 2012. Energy balance and obesity. Circulation 126, 
126–132. 
Holmes, L.B., Mittendorf, R., Shen, A., Smith, C.R., Hernandez-Diaz, S., 2011. Fetal 
effects of anticonvulsant polytherapies: different risks from different drug combi-
nations. Arch. Neurol. 68, 1275–1281. 
Hopkinson, Z.E., Sattar, N., Fleming, R., Greer, I.A., 1998. Polycystic ovarian 
syndrome: the metabolic syndrome comes to gynaecology. BMJ 317, 329–332. 
Hu, X., Wang, J., Dong, W., Fang, Q., Hu, L., Liu, C., 2011. A meta-analysis of poly-
cystic ovary syndrome in women taking valproate for epilepsy. Epilepsy Res. 97, 
73–82. 
Isojarvi, J., 2008. Disorders of reproduction in patients with epilepsy: antiepileptic drug 
related mechanisms. Seizure 17, 111–119. 
62 
Isojarvi, J.I., Laatikainen, T.J., Knip, M., Pakarinen, A.J., Juntunen, K.T., Myllyla, V.V., 
1996. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann. 
Neurol. 39, 579–584. 
Isojarvi, J.I., Laatikainen, T.J., Pakarinen, A.J., Juntunen, K.T., Myllyla, V.V., 1993. 
Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. 
N. Engl. J. Med. 329, 1383–1388. 
Isojarvi, J.I., Tauboll, E., Pakarinen, A.J., van Parys, J., Rattya, J., Harbo, H.F., Dale, 
P.O., Fauser, B.C., Gjerstad, L., Koivunen, R., Knip, M., Tapanainen, J.S., 2001a. 
Altered ovarian function and cardiovascular risk factors in valproate-treated women. 
Am. J. Med. 111, 290–296. 
Isojarvi, J.I., Tauboll, E., Tapanainen, J.S., Pakarinen, A.J., Laatikainen, T.J., Knip, M., 
Myllyla, V.V., 2001b. On the association between valproate and polycystic ovary 
syndrome: a response and an alternative view. Epilepsia 42, 305–310. 
Isomaa, B., Almgren, P., Tuomi, T., Forsen, B., Lahti, K., Nissen, M., Taskinen, M.R., 
Groop, L., 2001. Cardiovascular morbidity and mortality associated with the 
metabolic syndrome. Diabetes Care 24, 683–689. 
Janszky, I., Hallqvist, J., Tomson, T., Ahlbom, A., Mukamal, K.J., Ahnve, S., 2009. In-
creased risk and worse prognosis of myocardial infarction in patients with prior 
hospitalization for epilepsy – the Stockholm Heart Epidemiology Program. Brain 
132, 2798–2804. 
Johannessen, C.U., Johannessen, S.I., 2003. Valproate: past, present, and future. CNS 
Drug Rev 9, 199–216. 
Katsiki, N., Mikhailidis, D.P., Nair, D.R., 2014. The effects of antiepileptic drugs on 
vascular risk factors: a narrative review. Seizure 23, 677–684. 
Khan, S., Jena, G., 2016. Valproic Acid Improves Glucose Homeostasis by Increasing 
Beta-Cell Proliferation, Function, and Reducing its Apoptosis through HDAC 
Inhibition in Juvenile Diabetic Rat. J. Biochem. Mol. Toxicol. 
Khan, S., Kumar, S., Jena, G., 2016. Valproic acid reduces insulin-resistance, fat de-
position and FOXO1-mediated gluconeogenesis in type-2 diabetic rat. Biochimie 
125, 42–52. 
Kim, J.Y., Lee, H.W., 2007. Metabolic and hormonal disturbances in women with 
epilepsy on antiepileptic drug monotherapy. Epilepsia 48, 1366–1370. 
Klein, J.M., Busch, J.D., Potting, C., Baker, M.J., Langer, T., Schwarz, G., 2012. The 
mitochondrial amidoxime-reducing component (mARC1) is a novel signal-anchored 
protein of the outer mitochondrial membrane. J. Biol. Chem. 287, 42795–42803. 
Kobayashi, D., Hirayama, M., Komohara, Y., Mizuguchi, S., Wilson Morifuji, M., 
Ihn, H., Takeya, M., Kuramochi, A., Araki, N., 2014. Translationally controlled 
tumor protein is a novel biological target for neurofibromatosis type 1-associated 
tumors. J. Biol. Chem. 289, 26314–26326. 
Konig, S.A., Siemes, H., Blaker, F., Boenigk, E., Gross-Selbeck, G., Hanefeld, F., 
Haas, N., Kohler, B., Koelfen, W., Korinthenberg, R., et al., 1994. Severe hepa-
totoxicity during valproate therapy: an update and report of eight new fatalities. 
Epilepsia 35, 1005–1015. 
Krem, M.M., Luo, P., Ing, B.I., Horwitz, M.S., 2012. The kelch protein KLHDC8B 
guards against mitotic errors, centrosomal amplification, and chromosomal 
instability. J. Biol. Chem. 287, 39083–39093. 
LaBuzetta, J.N., Yao, J.Z., Bourque, D.L., Zivin, J., 2010. Adult nonhepatic hyper-
ammonemia: a case report and differential diagnosis. Am. J. Med. 123, 885–891. 
63 
Lagace, D.C., McLeod, R.S., Nachtigal, M.W., 2004. Valproic acid inhibits leptin 
secretion and reduces leptin messenger ribonucleic acid levels in adipocytes. 
Endocrinology 145, 5493–5503. 
Lakhanpal, D., Kataria, H., Kaur, G., 2011. Neuroendocrine plasticity in GnRH release 
is disrupted by valproic acid treatment of cycling rats. Acta Neurol. Belg. 111, 121–
129. 
Lakhanpal, D., Kaur, G., 2007. Valproic acid alters GnRH-GABA interactions in 
cycling female rats. Cell. Mol. Neurobiol. 27, 1069–1083. 
Lakka, H.M., Laaksonen, D.E., Lakka, T.A., Niskanen, L.K., Kumpusalo, E., Tuomi-
lehto, J., Salonen, J.T., 2002. The metabolic syndrome and total and cardiovascular 
disease mortality in middle-aged men. JAMA 288, 2709–2716. 
Levy, R.H., 2002. Antiepileptic drugs. 
Loria, P., Adinolfi, L.E., Bellentani, S., Bugianesi, E., Grieco, A., Fargion, S., Gasbar-
rini, A., Loguercio, C., Lonardo, A., Marchesini, G., Marra, F., Persico, M., Prati, D., 
Baroni, G.S., 2010. Practice guidelines for the diagnosis and management of 
nonalcoholic fatty liver disease. A decalogue from the Italian Association for the 
Study of the Liver (AISF) Expert Committee. Dig. Liver Dis. 42, 272–282. 
Loscher, W., 1999. Valproate: a reappraisal of its pharmacodynamic properties and 
mechanisms of action. Prog. Neurobiol. 58, 31–59. 
Luef, G., Abraham, I., Haslinger, M., Trinka, E., Seppi, K., Unterberger, I., Alge, A., 
Windisch, J., Lechleitner, M., Bauer, G., 2002a. Polycystic ovaries, obesity and 
insulin resistance in women with epilepsy. A comparative study of carbamazepine 
and valproic acid in 105 women. J. Neurol. 249, 835–841. 
Luef, G., Abraham, I., Hoppichler, F., Trinka, E., Unterberger, I., Bauer, G., Lech-
leitner, M., 2002b. Increase in postprandial serum insulin levels in epileptic patients 
with valproic acid therapy. Metabolism 51, 1274–1278. 
Luef, G., Abraham, I., Trinka, E., Alge, A., Windisch, J., Daxenbichler, G., Unter-
berger, I., Seppi, K., Lechleitner, M., Kramer, G., Bauer, G., 2002c. Hyperandro-
genism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study 
of women with epilepsy treated with valproate. Epilepsy Res. 48, 91–102. 
Luef, G., Rauchenzauner, M., Waldmann, M., Sturm, W., Sandhofer, A., Seppi, K., 
Trinka, E., Unterberger, I., Ebenbichler, C.F., Joannidis, M., Walser, G., Bauer, G., 
Hoppichler, F., Lechleitner, M., 2009. Non-alcoholic fatty liver disease (NAFLD), 
insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res. 86, 
42–47. 
Luef, G.J., Lechleitner, M., Bauer, G., Trinka, E., Hengster, P., 2003. Valproic acid 
modulates islet cell insulin secretion: a possible mechanism of weight gain in epi-
lepsy patients. Epilepsy Res. 55, 53–58. 
Luef, G.J., Waldmann, M., Sturm, W., Naser, A., Trinka, E., Unterberger, I., Bauer, G., 
Lechleitner, M., 2004. Valproate therapy and nonalcoholic fatty liver disease. Ann. 
Neurol. 55, 729–732. 
Macritchie, K., Geddes, J.R., Scott, J., Haslam, D., de Lima, M., Goodwin, G., 2003. 
Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev, 
Cd004052. 
Manaka, K., Nakata, M., Shimomura, K., Rita, R.S., Maejima, Y., Yoshida, M., Dezaki, K., 
Kakei, M., Yada, T., 2014. Chronic exposure to valproic acid promotes insulin 
release, reduces KATP channel current and does not affect Ca (2+) signaling in 
mouse islets. J. Physiol. Sci. 64, 77–83. 
64 
Martin, C.K., Han, H., Anton, S.D., Greenway, F.L., Smith, S.R., 2009. Effect of 
valproic acid on body weight, food intake, physical activity and hormones: results of 
a randomized controlled trial. J Psychopharmacol 23, 814–825. 
Masuccio, F., Verrotti, A., Chiavaroli, V., de Giorgis, T., Giannini, C., Chiarelli, F., 
Mohn, A., 2010. Weight gain and insulin resistance in children treated with 
valproate: the influence of time. J. Child Neurol. 25, 941–947. 
McCarthy, D.J., Chen, Y., Smyth, G.K., 2012. Differential expression analysis of multi-
factor RNA-Seq experiments with respect to biological variation. Nucleic Acids 
Res. 40, 4288–4297. 
McLean, M.J., Macdonald, R.L., 1986. Sodium valproate, but not ethosuximide, 
produces use- and voltage-dependent limitation of high frequency repetitive firing of 
action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 
237, 1001–1011. 
Morrell, M.J., Giudice, L., Flynn, K.L., Seale, C.G., Paulson, A.J., Done, S., Flaster, E., 
Ferin, M., Sauer, M.V., 2002. Predictors of ovulatory failure in women with epi-
lepsy. Ann. Neurol. 52, 704–711. 
Morrell, M.J., Hayes, F.J., Sluss, P.M., Adams, J.M., Bhatt, M., Ozkara, C., Warnock, 
C.R., Isojarvi, J., 2008. Hyperandrogenism, ovulatory dysfunction, and polycystic 
ovary syndrome with valproate versus lamotrigine. Ann. Neurol. 64, 200–211. 
Morrell, M.J., Isojarvi, J., Taylor, A.E., Dam, M., Ayala, R., Gomez, G., O'Neill, F., 
Tennis, P., Messenheimer, J., 2003. Higher androgens and weight gain with 
valproate compared with lamotrigine for epilepsy. Epilepsy Res. 54, 189–199. 
Moshe, S.L., Perucca, E., Ryvlin, P., Tomson, T., 2015. Epilepsy: new advances. Lancet 
385, 884–898. 
Mulleners, W.M., McCrory, D.C., Linde, M., 2015. Antiepileptics in migraine pro-
phylaxis: an updated Cochrane review. Cephalalgia 35, 51–62. 
Munzberg, H., Myers, M.G., Jr., 2005. Molecular and anatomical determinants of 
central leptin resistance. Nat. Neurosci. 8, 566–570. 
Murialdo, G., Galimberti, C.A., Gianelli, M.V., Rollero, A., Polleri, A., Copello, F., 
Magri, F., Ferrari, E., Sampaolo, P., Manni, R., Tartara, A., 1998. Effects of val-
proate, phenobarbital, and carbamazepine on sex steroid setup in women with 
epilepsy. Clin. Neuropharmacol. 21, 52–58. 
Murphy, J.V., Marquardt, K., 1982. Asymptomatic hyperammonemia in patients 
receiving valproic acid. Arch. Neurol. 39, 591–592. 
Nair, S.S., Harikrishnan, S., Sarma, P.S., Thomas, S.V., 2016. Metabolic syndrome in 
young adults with epilepsy. Seizure 37, 61–64. 
Nanau, R.M., Neuman, M.G., 2013. Adverse drug reactions induced by valproic acid. 
Clin. Biochem. 46, 1323–1338. 
Nebert, D.W., Russell, D.W., 2002. Clinical importance of the cytochromes P450. 
Lancet 360, 1155–1162. 
Nelson-DeGrave, V.L., Wickenheisser, J.K., Cockrell, J.E., Wood, J.R., Legro, R.S., 
Strauss, J.F., 3rd, McAllister, J.M., 2004. Valproate potentiates androgen bio-
synthesis in human ovarian theca cells. Endocrinology 145, 799–808. 
Nevalainen, O., Ansakorpi, H., Simola, M., Raitanen, J., Isojarvi, J., Artama, M., 
Auvinen, A., 2014. Epilepsy-related clinical characteristics and mortality: a 
systematic review and meta-analysis. Neurology 83, 1968–1977. 
Novak, G.P., Maytal, J., Alshansky, A., Eviatar, L., Sy-Kho, R., Siddique, Q., 1999. 
Risk of excessive weight gain in epileptic children treated with valproate. J. Child 
Neurol. 14, 490–495. 
65 
Obici, S., Feng, Z., Morgan, K., Stein, D., Karkanias, G., Rossetti, L., 2002. Central 
administration of oleic acid inhibits glucose production and food intake. Diabetes 
51, 271–275. 
Ornoy, A., 2009. Valproic acid in pregnancy: how much are we endangering the 
embryo and fetus? Reprod. Toxicol. 28, 1–10. 
Palin, E.J., Lesonen, A., Farr, C.L., Euro, L., Suomalainen, A., Kaguni, L.S., 2010. 
Functional analysis of H. sapiens DNA polymerase gamma spacer mutation W748S 
with and without common variant E1143G. Biochim. Biophys. Acta 1802, 545–551. 
Panayiotopoulos, C.P., 2010. Atlas of epilepsies. Springer, London ; New York. 
Perucca, E., 2002. Pharmacological and therapeutic properties of valproate: a summary 
after 35 years of clinical experience. CNS Drugs 16, 695–714. 
Perucca, E., 2013. Optimizing antiepileptic drug treatment in tumoral epilepsy. Epi-
lepsia 54 Suppl 9, 97–104. 
Phiel, C.J., Zhang, F., Huang, E.Y., Guenther, M.G., Lazar, M.A., Klein, P.S., 2001. 
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood 
stabilizer, and teratogen. J. Biol. Chem. 276, 36734–36741. 
Pocai, A., Lam, T.K., Gutierrez-Juarez, R., Obici, S., Schwartz, G.J., Bryan, J., Aguilar-
Bryan, L., Rossetti, L., 2005. Hypothalamic K(ATP) channels control hepatic 
glucose production. Nature 434, 1026–1031. 
Pohlmann-Eden, B., Peters, C.N., Wennberg, R., Dempfle, C.E., 2003. Valproate 
induces reversible factor XIII deficiency with risk of perioperative bleeding. Acta 
Neurol. Scand. 108, 142–145. 
Pourahmad, J., Eskandari, M.R., Kaghazi, A., Shaki, F., Shahraki, J., Fard, J.K., 2012. 
A new approach on valproic acid induced hepatotoxicity: involvement of lysosomal 
membrane leakiness and cellular proteolysis, Toxicol. In Vitro. 2012 Elsevier Ltd, 
England, pp. 545–551. 
Prabhakar, S., Sahota, P., Kharbanda, P.S., Siali, R., Jain, V., Lal, V., Khurana, D., 
2007. Sodium valproate, hyperandrogenism and altered ovarian function in Indian 
women with epilepsy: a prospective study. Epilepsia 48, 1371–1377. 
Privitera, M.D., Brodie, M.J., Mattson, R.H., Chadwick, D.W., Neto, W., Wang, S., 
2003. Topiramate, carbamazepine and valproate monotherapy: double-blind com-
parison in newly diagnosed epilepsy. Acta Neurol. Scand. 107, 165–175. 
Psaras, T., Will, B.E., Schoeber, W., Rona, S., Mittelbronn, M., Honegger, J.B., 2008. 
Quantitative assessment of postoperative blood collection in brain tumor surgery 
under valproate medication. Zentralbl. Neurochir. 69, 165–169. 
Pylvanen, V., Knip, M., Pakarinen, A., Kotila, M., Turkka, J., Isojarvi, J.I., 2002. Serum 
insulin and leptin levels in valproate-associated obesity. Epilepsia 43, 514–517. 
Pylvanen, V., Knip, M., Pakarinen, A.J., Turkka, J., Kotila, M., Rattya, J., Myllyla, 
V.V., Isojarvi, J.I., 2003. Fasting serum insulin and lipid levels in men with epi-
lepsy. Neurology 60, 571–574. 
Pylvanen, V., Pakarinen, A., Knip, M., Isojarvi, J., 2006a. Characterization of insulin 
secretion in Valproate-treated patients with epilepsy. Epilepsia 47, 1460–1464. 
Pylvanen, V., Pakarinen, A., Knip, M., Isojarvi, J., 2006b. Insulin-related metabolic 
changes during treatment with valproate in patients with epilepsy. Epilepsy Behav. 
8, 643–648. 
Qiao, L., Schaack, J., Shao, J., 2006. Suppression of adiponectin gene expression by 
histone deacetylase inhibitor valproic acid. Endocrinology 147, 865–874. 
66 
Rattya, J., Vainionpaa, L., Knip, M., Lanning, P., Isojarvi, J.I., 1999. The effects of 
valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in 
girls with epilepsy. Pediatrics 103, 588–593. 
Rauchenzauner, M., Haberlandt, E., Scholl-Burgi, S., Karall, D., Schoenherr, E., 
Tatarczyk, T., Engl, J., Laimer, M., Luef, G., Ebenbichler, C.F., 2008. Effect of 
valproic acid treatment on body composition, leptin and the soluble leptin receptor 
in epileptic children. Epilepsy Res. 80, 142–149. 
Reaven, G.M., 1988. Banting lecture 1988. Role of insulin resistance in human disease. 
Diabetes 37, 1595–1607. 
Robert, E., Guibaud, P., 1982. Maternal valproic acid and congenital neural tube 
defects. Lancet 2, 937. 
Robinson, M.D., McCarthy, D.J., Smyth, G.K., 2010. edgeR: a Bioconductor package 
for differential expression analysis of digital gene expression data. Bioinformatics 
26, 139–140. 
Ross, E.L., 2000. The evolving role of antiepileptic drugs in treating neuropathic pain. 
Neurology 55, S41–46; discussion S54–48. 
Sahota, P., Prabhakar, S., Kharbanda, P.S., Bhansali, A., Jain, V., Das, C.P., Modi, M., 
2008. Seizure type, antiepileptic drugs, and reproductive endocrine dysfunction in 
Indian women with epilepsy: a cross-sectional study. Epilepsia 49, 2069–2077. 
Schmidt, D., Schachter, S.C., 2014. Drug treatment of epilepsy in adults. BMJ 348, 
g254. 
Schwartz, M.W., Woods, S.C., Porte, D., Jr., Seeley, R.J., Baskin, D.G., 2000. Central 
nervous system control of food intake. Nature 404, 661–671. 
Shahien, R., Saleh, S.A., Bowirrat, A., 2011. Intravenous sodium valproate aborts 
migraine headaches rapidly. Acta Neurol. Scand. 123, 257–265. 
Shakespear, M.R., Halili, M.A., Irvine, K.M., Fairlie, D.P., Sweet, M.J., 2011. Histone 
deacetylases as regulators of inflammation and immunity. Trends Immunol. 32, 
335–343. 
Sheridan, D., Sun, B., O'Brien, P., Hansen, M., 2015. Intravenous Sodium Valproate for 
Acute Pediatric Headache. J. Emerg. Med. 49, 541–545. 
Silva, M.F., Aires, C.C., Luis, P.B., Ruiter, J.P., L, I.J., Duran, M., Wanders, R.J., 
Tavares de Almeida, I., 2008. Valproic acid metabolism and its effects on mito-
chondrial fatty acid oxidation: a review. J. Inherit. Metab. Dis. 31, 205–216. 
Steinhoff, B.J., Neususs, K., Thegeder, H., Reimers, C.D., 1996. Leisure time activity 
and physical fitness in patients with epilepsy. Epilepsia 37, 1221–1227. 
Stephen, L.J., Kwan, P., Shapiro, D., Dominiczak, M., Brodie, M.J., 2001. Hormone 
profiles in young adults with epilepsy treated with sodium valproate or lamotrigine 
monotherapy. Epilepsia 42, 1002–1006. 
Storey, J.D., Tibshirani, R., 2003. Statistical significance for genomewide studies. Proc. 
Natl. Acad. Sci. U. S. A. 100, 9440–9445. 
Sudhop, T., Bauer, J., Elger, C.E., von Bergmann, K., 1999. Increased high-density 
lipoprotein cholesterol in patients with epilepsy treated with carbamazepine: a 
gender-related study. Epilepsia 40, 480–484. 
Zaccara, G., Campostrini, R., Paganini, M., Messori, A., Valenza, T., Arnetoli, G., 
Zappoli, R., 1987. Long-term treatment with sodium valproate: monitoring of 
venous ammonia concentrations and adverse effects. Ther. Drug Monit. 9, 34–40. 
Zeise, M.L., Kasparow, S., Zieglgansberger, W., 1991. Valproate suppresses N-methyl-
D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res. 
544, 345–348. 
67 
Zeller, J.A., Schlesinger, S., Runge, U., Kessler, C., 1999. Influence of valproate mono-
therapy on platelet activation and hematologic values. Epilepsia 40, 186–189. 
Zhang, X.Z., Li, X.J., Zhang, H.Y., 2010. Valproic acid as a promising agent to combat 
Alzheimer’s disease. Brain Res. Bull. 81, 3–6. 
Zighetti, M.L., Fontana, G., Lussana, F., Chiesa, V., Vignoli, A., Canevini, M.P., 
Cattaneo, M., 2015. Effects of chronic administration of valproic acid to epileptic 
patients on coagulation tests and primary hemostasis. Epilepsia 56, e49–52. 
Tang, Y., Glauser, T.A., Gilbert, D.L., Hershey, A.D., Privitera, M.D., Ficker, D.M., 
Szaflarski, J.P., Sharp, F.R., 2004. Valproic acid blood genomic expression patterns 
in children with epilepsy – a pilot study. Acta Neurol. Scand. 109, 159–168. 
Taylor, A.E., 1998. Polycystic ovary syndrome. Endocrinol. Metab. Clin. North Am. 
27, 877–902, ix. 
Terasmaa, A., Soomets, U., Oflijan, J., Punapart, M., Hansen, M., Matto, V., Ehrlich, K., 
Must, A., Koks, S., Vasar, E., 2011. Wfs1 mutation makes mice sensitive to insulin-
like effect of acute valproic acid and resistant to streptozocin. J. Physiol. Biochem. 
67, 381–390. 
Tetzlaff, J.E., 1991. Intraoperative defect in haemostasis in a child receiving valproic 
acid. Can. J. Anaesth. 38, 222–224. 
Tomson, T., 2015. Commentary: Valproate in the treatment of epilepsy in women and 
girls: The need for recommendations. Epilepsia 56, 1004–1005. 
Tomson, T., Battino, D., 2012. Teratogenic effects of antiepileptic drugs. Lancet 
Neurol. 11, 803–813. 
Tomson, T., Battino, D., Bonizzoni, E., Craig, J., Lindhout, D., Perucca, E., Sabers, A., 
Thomas, S.V., Vajda, F., Group, E.S., 2015a. Dose-dependent teratogenicity of val-
proate in mono- and polytherapy: an observational study. Neurology 85, 866–872. 
Tomson, T., Battino, D., Bonizzoni, E., Craig, J., Lindhout, D., Sabers, A., Perucca, E., 
Vajda, F., 2011. Dose-dependent risk of malformations with antiepileptic drugs: an 
analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 
10, 609–617. 
Tomson, T., Battino, D., Perucca, E., 2015b. Valproic acid after five decades of use in 
epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol. 
Tomson, T., Marson, A., Boon, P., Canevini, M.P., Covanis, A., Gaily, E., Kalviainen, 
R., Trinka, E., 2015c. Valproate in the treatment of epilepsy in girls and women of 
childbearing potential. Epilepsia 56, 1006–1019. 
Trinka, E., Hofler, J., Leitinger, M., Brigo, F., 2015. Pharmacotherapy for Status 
Epilepticus. Drugs 75, 1499–1521. 
Trinka, E., Hofler, J., Zerbs, A., Brigo, F., 2014. Efficacy and safety of intravenous val-
proate for status epilepticus: a systematic review. CNS Drugs 28, 623–639. 
Turnbull, D.M., Bone, A.J., Tames, F.J., Wilson, L., Baird, J.D., Sherratt, H.S., 1985. 
The effect of valproate on blood metabolite concentrations in spontaneously 
diabetic, ketoacidotic, BB/E Wistar rats. Diabetes Res. 2, 45–48. 
Wagner, P.G., Welton, S.R., Hammond, C.M., 2000. Gastrointestinal adverse effects 
with divalproex sodium and valproic acid. J. Clin. Psychiatry 61, 302–303. 
Vajda, F.J., Hitchcock, A.A., Graham, J., O'Brien, T.J., Lander, C.M., Eadie, M.J., 
2010. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 51, 805–810. 
Van Lint, C., Emiliani, S., Verdin, E., 1996. The expression of a small fraction of 
cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5, 
245–253. 
68 
Wang, B., Liu, Y., He, P., Dong, B., OuYang, L., Ma, Y., Yang, L., 2010. Prevalence of 
metabolic syndrome in an elderly Chinese population: a community-based cross-
sectional study. J. Am. Geriatr. Soc. 58, 2027–2028. 
Ward, M.M., Barbaro, N.M., Laxer, K.D., Rampil, I.J., 1996. Preoperative valproate 
administration does not increase blood loss during temporal lobectomy. Epilepsia 
37, 98–101. 
Wayne, P., 2013. CLSI. Measurement procedure comparison and bias estimation using 
patient samples; Approved guideline-Third edition. CLSI document EP09-A3. 
Clinical and laboratory standards institute. 
Weller, M., Gorlia, T., Cairncross, J.G., van den Bent, M.J., Mason, W., Belanger, K., 
Brandes, A.A., Bogdahn, U., Macdonald, D.R., Forsyth, P., Rossetti, A.O., 
Lacombe, D., Mirimanoff, R.O., Vecht, C.J., Stupp, R., 2011. Prolonged survival 
with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. 
Neurology 77, 1156–1164. 
Verrotti, A., Agostinelli, S., Parisi, P., Chiarelli, F., Coppola, G., 2011a. Nonalcoholic 
fatty liver disease in adolescents receiving valproic acid. Epilepsy Behav. 20, 382–
385. 
Verrotti, A., Basciani, F., Morresi, S., de Martino, M., Morgese, G., Chiarelli, F., 1999. 
Serum leptin changes in epileptic patients who gain weight after therapy with 
valproic acid. Neurology 53, 230–232. 
Verrotti, A., D’Egidio, C., Mohn, A., Coppola, G., Chiarelli, F., 2011b. Weight gain fol-
lowing treatment with valproic acid: pathogenetic mechanisms and clinical 
implications. Obes. Rev. 12, e32–43. 
Verrotti, A., D'Egidio, C., Mohn, A., Coppola, G., Parisi, P., Chiarelli, F., 2011c. Anti-
epileptic drugs, sex hormones, and PCOS. Epilepsia 52, 199–211. 
Verrotti, A., la Torre, R., Trotta, D., Mohn, A., Chiarelli, F., 2009. Valproate-induced 
insulin resistance and obesity in children. Horm. Res. 71, 125–131. 
Verrotti, A., Manco, R., Agostinelli, S., Coppola, G., Chiarelli, F., 2010. The metabolic 
syndrome in overweight epileptic patients treated with valproic acid. Epilepsia 51, 
268–273. 
Vyas, M.V., Davidson, B.A., Escalaya, L., Costella, J., Saposnik, G., Burneo, J.G., 
2015. Antiepileptic drug use for treatment of epilepsy and dyslipidemia: Systematic 
review. Epilepsy Res. 113, 44–67. 
Yagi, R., Tanaka, M., Sasaki, K., Kamata, R., Nakanishi, Y., Kanai, Y., Sakai, R., 2011. 
ARAP3 inhibits peritoneal dissemination of scirrhous gastric carcinoma cells by 




9. SUMMARY IN ESTONIAN 
Valproaadi metaboolsed mõjud epilepsiaga patsientidel  
akuutse ja kroonilise ravi puhul 
Valproaat (VPA) on maailmas laialt kasutatav epileptiliste hoogude kontrolli-
miseks mõeldud preparaat, mida erinevatel hinnangutel iga päev kasutab rohkem 
kui üks miljon inimest (Farinelli et al., 2015; Perucca, 2002). Selle ravimi anti-
konvulsiivse toime avastas 1962. aastal prantsuse teadlane Pierre Eymard (Cha-
teauvieux et al., 2010). Vaatamata sellele, et viimase 50 aasta jooksul on sün-
teesitud rohkem kui kümme uut antikonvulsanti, on VPA esmavaliku prepa-
raadiks paljude epilepsia vormide puhul (Perucca, 2002). VPA-d kasutatakse ka 
bipolaarsele häirete ravis, diabeetilise polüneuropaatiaga kaasuva valu ravis, 
migreeni profülaktikas (Bril et al., 2011; Nanau and Neuman, 2013). Hiljuti 
hakati seda ravimit kasutama ka teatud pahaloomuliste kasvajate ravis (Weller 
et al., 2011). Kuna tegemist on pikaajalist ravi vajavate krooniliste haigustega, 
on väga oluline tagada kasutatavate preparaatide ohutus ja vastuvõetav kõrval-
toimete profiil kestval kasutamisel. VPA sagedaste kõrvaltoimete hulka kuuluvad 
posturaalne treemor, juuste väljalangemine, hüperammoneemia, gastrointesti-
naalsed ja hematoloogilised kõrvaltoimed, maksatoksilisus (Perucca, 2002). 
Antud ravim mõjutab ka embrüogeneesi, põhjustades kaasasündinud ano-
maaliaid ja käitumishäireid lastel, kelle emad kasutasid VPA-d raseduse ajal 
(Tomson and Battino, 2012). Kõige sagedasemaks VPA kõrvaltoimeks peetakse 
siiski kehakaalu tõusu. Selle probleemi levimus pole täpselt teada, erinevatel 
andmetel võib kehakaalu tõus esineda kuni pooltel VPA-d tarvitavatel haigetel. 
Ei ole ka täpselt teada VPA-st tingitud kaalutõusu molekulaarsed mehhanismid 
(Verrotti et al., 2009). Kehakaalu tõusuga võivad sageli kaasneda metaboolsed 
ja endokriinsed häired, mida hästi kirjeldab metaboolse sündroomi kontsept-
sioon (Reaven, 1988).  
Metaboolne sündroom on riskifaktorite (rasvumine, glükoosiregulatsiooni 
häired, hüpertensioon ja düslipideemia) kogum, mille puhul esineb kõrgem risk 
haigestuda 2. tüüpi diabeeti ja südameveresoonkonna haigustesse (Eckel et al., 
2005). Seoses istuva eluviisi ja antikonvulsantide kõrvaltoimetega võib epi-
lepsiaga patsientidel olla kõrgem metaboolse sündroomi risk (Ben-Menachem, 
2007; Steinhoff et al., 1996). Üsna vähe on tehtud uuringuid, mis kirjeldaksid 
metaboolse sündroomi levimust ja riskifaktoreid nendel patsientidel. Osa 
autoreid väidavad, et VPA-d tarvitavatel patsientidel on metaboolse sündroomi 
risk tõusnud, teised aga seda seost ei leia (Kim and Lee, 2007; Verrotti et al., 
2010). Enamus nendest uuringutest on fokuseerunud spetsiifilistele populat-
sioonidele nagu lapsed või naised ja populatsiooni-põhiseid uuringuid sellel 







1. Hinnata metaboolse sündroomi ja selle komponentide levimust VPA-d tarvi-
tavatel epilepsiaga inimestel ja võrrelda seda üldpopulatsiooniga.  
2. Võrrelda metaboolse sündroomi esinemissagedust ja riskitegureid VPA-d ja 
karbamasepiini (CBZ) tarvitavatel epilepsiaga patsientidel.  
3. Iseloomustada boolusena veeni manustatava VPA mõju glükoosi, insuliini ja 
C-peptiidi vere kontsentratsioonile esmaselt diagnoositud epilepsiaga pat-
sientidel vahetult pärast esmast ekspositsiooni. 
4. Hinnata VPA toimet geeniekspressioonile perifeerses veres kolme kuu jook-
sul VPA ravi saanutel esmaselt diagnoositud epilepsiaga patsientidel. 
 
 
Uuritavad ja meetodid 
Uuringu kiitis heaks Tartu Ülikooli Inimuuringute Eetikakomitee ja kõik uuri-
tavad allkirjastasid kirjaliku informeeritud nõusoleku uuringus osalemiseks. 
Uuringu esimese ja teise eesmärgi täitmiseks on identifitseeritud kõik patsiendid 
kuues Lõuna-Eesti maakonnas, kes ostsid apteegist VPA-d ning Tartu linna ja 
maakonna patsiendid, kes ostsid apteegist CBZ-d epilepsia näidustusel. Selleks 
kasutati Eesti Haigekassa väljakirjutatud retseptiravimite andmebaasi. Patsienti-
dega võeti ühendust ja kutsuti uuringuvisiidile. Välistamiskriteeriumideks olid: 
vanus ≤ 18 aastat, VPA- või CBZ- monoteraapia kestusega < 3 kuud, polü-
teraapia teiste antikonvulsantidega, rasedus. Uuringusse ei haaratud patsiente, 
kellel oli seoses ajukahjustusega tõsine füüsiline või vaimne puue. Siia kuulusid 
kõik patsiendid, kes viibisid uuringu ajal hooldekodudes või vajasid kõrval-
isikute abi oma igapäevastes toimingutes. Endokriinsete häiretega patsiendid ei 
olnud välistatud. VPA-d tarvitavate patsientide andmete kogumine toimus 
perioodil 01.01.2012-31.12.2012 ja CBZ-d tarvitavate patsientide andmete 
kogumine perioodil 01.12.2014–1.09.2015. Esialgses andmebaasis oli 384 (206 
meest ja 178 naist) VPA-d tarvitavat ja 484 (292 meest ja 192 naist) CBZ-d 
tarvitavat patsienti. Pärast väljaarvamise kriteeriumide kasutamist on jäänud 
118 (63 meest ja 55 naist) VPA-d tarvitavat ja 95 (55 meest ja 40 naist) CBZ-d 
tarvitavat patsienti. Uuring toimus Tartu Ülikooli Närvikliinikus. Kõik uurin-
gusse arvatud patsiendid kutsuti visiidile. Iga patsiendi kohta täideti protokoll, 
mis sisaldas isikuandmeid, epilepsia ja muude haiguste anamneesi. Epileptilised 
sündroomid olid klassifitseeritud Rahvusvahelise Epilepsiavastase Liiga juht-
nööride alusel (Berg et al., 2010). Fikseeriti vastava antikonvulsandi annus ja 
ravi kestus. Patsientidel mõõdeti vererõhk, vööümbermõõt, pikkus ja kaal ning 
määrati paastuplasmast glükoosi, HDL-kolesterooli, triglütseriidide, insuliini, 
C-peptiidi ja VPA või CBZ plasmakontsentratsioon.  
Metaboolse sündroomi hindamiseks kasutati Rahvusvahelise Kolesterooli 
Õppeprogrammi Täiskasvanute III Ravipaneeli (NCEP ATP III) kriteeriume. 
Kontrollgruppi kuulusid isikud, kes osalesid Lõuna-Eesti rahvastikupõhises 
läbilõikeuuringus aastatel 2008–2009 (Eglit et al., 2012). Kontrollisikuid valiti 
juhuslikult nelja Lõuna-Eesti perearsti nimistutest ning kutsuti uuringust osa 
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võtma kirja teel, vastamismäär oli 53% (493 isikut). Kontrollgrupi struktuur 
vastas Eesti rahvastiku vanuselisele ja soolisele struktuurile. 
Uuringu kolmanda eesmärgi täitmiseks pakuti patsientidele, kellel oli esmaselt 
diagnoositud epilepsia ja näidustatud antikonvulsantravi alustamine valproaadiga, 
saada esimene VPA annust intravenoosselt (n = 16). Selle uuringu osa protokoll 
eeldas kahte visiiti. Esimese visiidi ajal tehti patsientidele glükoositaluvuse proov. 
Plasma glükoosi-, insuliini- ja C-peptiidi sisaldust määrati enne testi algust ning 
1 ja 2 tundi pärast 75 grammi glükoosilahuse joomist. Teise visiidi ajal, mis toi-
mus mitte rohkem kui 7 päeva pärast, korrati glükoositaluvuse proovi, kuid 
vahetult enne glükoosilahuse joomist manustati veenisiseselt 900–1800 mg 
VPA (Orfiril, Desitin), mis oli lahustatud 0.9% NaCl 100 ml-s. Selle protse-
duuri ajal jälgiti pulssi, vererõhku ja punktsiooni koha ärrituse nähtusid.  
Uuringu neljanda eesmärgi täitmiseks esmaselt diagnoositud epilepsiaga pat-
sientidel on võetud vereanalüüs RNA eraldamiseks ja geeniekspressiooni 
analüüsimiseks enne ravi ja 3 kuud pärast VPA monoteraapia algust (n = 9). 
Keskmine VPA päevaannus oli 11.4 ± 2.8 mg/kg. Geeniekspressiooni erinevust 
hinnati Affymetrix GeneChip analüsaatoriga. 
 
 
Peamised tulemused ja arutelu 
Metaboolse sündroomi levimus VPA-d tarvitavatel epilepsiaga patsientidel 
Metaboolse sündroomi kaalutud levimus VPA-monoteraapial olevatel patsienti-
del on 25.8% (95% CI, 18.4–34.8%), mis oluliselt ei erine selle sündroomi levi-
musest Eesti üldpopulatsioonis 27.9% (95% CI, 24.0–32.1%). Logistilise 
regressiooni analüüs samuti näitas, et metaboolse sündroomi esinemise riski-
suhe VPA-d tarvitavatel patsientidel ja kontrollisikutel on 1.00; 95% CI, 0.59–
1.68; P = 0.998. Ka kehamassi indeksi näitajad ei erinenud oluliselt kahe 
kohordi vahel. Samas, sõltumata kehamassi indeksist, oli patsientidel, kes tarvi-
tasid VPA-d, kõrgem paastu insuliini kontsentratsioon veres. Tulemus viitab 
sellele, et hüperinsulineemia VPA-d tarvitavatel patsientidel ei ole kehakaalu 
tõusu tagajärg, vaid hoopis üks selle põhjustest. Võrreldes kontrollisikutega, oli 
HOMA-IR indeksil madalam ennustatav väärtus metaboolse sündroomi esine-
mise prognoosimisel VPA-d tarvitavatel patsientidel. Tõenäoliselt tähendab see, 
et antud indeks ei kajasta korrektselt insuliini resistentsuse esinemist nendel pat-
sientidel, kuna VPA mõjutab otseselt insuliini metabolismi. 
 
Metaboolse sündroomi esinemise ja selle riskifaktorite võrdlus VPA-d ja 
CBZ-d tarvitavatel epilepsiaga patsientidel  
Üks faktoritest, mis oli positiivselt seotud metaboolse sündroomi esinemise 
riskiga VPA-d või CBZ-d tarvitavatel epilepsiaga patsientidel, oli vanus (OR = 
1.03; 95% CI, 1.01–1.06; P = 0.007). See kajastab ilmselt paljude populat-
sioonide üldist trendi – kõrgema vanusega metaboolse sündroomi risk tõuseb. 
Pikem VPA kasutamine soodustas samuti metaboolse sündroomi riski (OR = 
1.01; 95% CI, 1.0–1.02; P < 0.01). Ka VPA annus oli tendentsina seotud meta-
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boolse sündroomi esinemise riskiga, piiripealse statistilise olulisusega (OR = 
1.11; 95% CI, 0.99 – 1.24; P = 0.075). Kuigi üldine metaboolse sündroomi 
esinemise risk VPA-d ja CBZ-d tarvitavatel patsientidel oli sarnane, oli selle 
sündroomi üksikute parameetrite jaotus erinev: VPA-d tarvitavatel patsientidel 
esines sagedamini madal HDL-C ja harvemini kõrge glükoosi kontsentratsioon 
veres. VPA-d tarvitavatel naistel esinesid sagedamini kaks metaboolse sünd-
roomi komponenti: suurenenud vöö ümbermõõt ja langenud HDL-C kontsent-
ratsioon veres. Seega, antikonvulsant-ravi planeerimisel esmaselt diagnoositud 
epilepsiaga patsientidel tuleb soovitada metaboolsete kõrvaltoimete tõenäosuse 
vähendamiseks minimaalset toimivat VPA annust. Naistel, kellel juba enne ravi 
algust esinesid metaboolsed häired, ei ole VPA kasutamine ekvivalentse alter-
natiivi olemasolul soovitav. 
 
Akuutse veenisisese VPA manustamise efekt glükoosi, insuliini ja  
C-peptiidi metabolismile 
Veenisisese VPA manustamine oli üldiselt hästi talutav. Pärast veenisisese VPA 
manustamist, glükoositaluvuse testi 120 minutil, langes patsientidel plasma glü-
koosi kontsentratsioon. Samas, insuliini ja C-peptiidi plasma kontsentratsioonid 
oluliselt ei muutunud. Akuutse veenisisese VPA manustamise glükoosi lange-
tavat efekti inimestel tuvastasime esmakordselt, varem seda kirjeldatud ei ole. 
Plasma glükoosisisalduse languse täpne molekulaarne mehhanism ei ole hetkel 
selge. Samas võib VPA otsene hüpogükeemiline toime ja sellega kaasnev või-
malik söögiisu suurenemine seletada kaalu muutusi VPA-d tarvitavatel pat-
sientidel. Töö tulemusena tekkis küsimus, kas on võimalik kasutada VPA-d dia-
beedi ravis arvestades selle ravimi glükoosi langetavat efekti. 
 
Kroonilise VPA-ravi efekt geeniekspressioonile perifeerses veres 
Analüüsitud geenidest (23099) leiti ainult 11 geeni ekspressiooni muutus (võrdlus 
enne uuringu algust ja 3 kuud hiljem). Analüütilist tarkvara (Ingenuity Pathway 
Analysis) kasutades, leiti, et aktiveeritud olid südame-veresoonkonna ja hema-
toloogilise süsteemi arengu ja funktsiooniga ning rakude morfoloogiaga seotud 
geneetilised rajad. Kuigi loomkatsetes on näidatud, et VPA võib mõjutada kuni 
5% geenide ekspressiooni, on madal aktivatsiooni tase meie uuringus ilmselt 
seotud suhteliselt madalate kasutatud VPA annustega (600–1200 mg päevas). 
VPA tugevat teratogeenset efekti seostatakse histoonide deatsetülaasi inhi-
beeriva toimega, mille tõttu võib paljude loote arengus osalevate geenide trans-
kriptsioon olla häiritud. Antud töö tulemused lubavad väita, et selle kõrvaltoime 






I would like to express my deepest gratitude to my academic supervisor, 
Associate Professor Sulev Haldre, who provided me the opportunity to carry out 
this study. My greatest thanks for his friendship and mentorship, and for being 
there with advice, especially in the difficult moments throughout the study. I am 
eternally thankful to my second academic supervisor, Professor Sulev Kõks, for 
the idea of the study, his friendly support, and expert advice, without which this 
thesis would probably have never been finished. 
I would like thank my co-author Professor Margus Lember, who introduced 
to me the basics of writing scientific papers and helped me in the process of 
manuscript preparation. I extend my sincere gratitude to my co-author and 
colleague, Dr. Triin Eglit, with whom I planned the first part of the study. Her 
previous work gave me many ideas on how to design the present study.  
I am extremely grateful to Professor Pille Taba and Professor Vallo Tillmann 
for reviewing the thesis and making several helpful suggestions and comments.  
My special thanks to Ele Prans, Ene Reimann, and Marilin Ivask from the 
Pathophysiology Department of the Center of Translational Medicine, Uni-
versity of Tartu, for sharing their rich experience in the area of genetics. Many 
thanks to Anton Terasmaa for his ideas during the design of the study.  
I am very grateful to Inge Ringmets for her expert opinion in statistics and 
help in analyzing the data.  
My warmest thanks go to all of my colleagues in the Department of Neuro-
logy and Neurosurgery of Tartu University Hospital for their positive support 
and understanding during and after the study period. I would also like to thank 
the nurses of the Neurology Clinic, Tartu University Hospital, and especially 
Jelena Gluštšenko for help in performing the anthropometric and laboratory 
measurements. Many thanks to Koidula Demitševa, who was the main guide for 
solving organizational tasks related to this work. 
My deepest gratitude to all of the patients who participated in this study and 
made this research project possible. 
Finally, I owe my deepest gratitude to my family, my wife Julia and children, 
for giving me the energy and time to be able to work on this study. This 
gratitude also extends to my grandparents, to whom this thesis is dedicated. 
The study was conducted at the Department of Neurology and Neurosurgery, 
University of Tartu. It was supported by Estonian Science Foundation grant no. 
ETF9309, targeted financing from the Estonian Ministry of Education and 
Research (no. SF0180081s07), and institutional research support from the 




















Name:  Aleksei Rakitin 
Date of birth:  02.09.1978, Tartu 
Citizenship:  Estonian 
Address:  L. Puusepp Street 8H, 51014, Tartu, Estonia 
Phone:  +372 731 8557 
E-mail:  Aleksei.Rakitin@kliinikum.ee 
Education: 
1985–1996  Tartu Annelinn Gymnasium 
1997–2003  University of Tartu, Faculty of Medicine 
2003–2007  University of Tartu, Faculty of Medicine, residency in neurology 
2010–  University of Tartu, Faculty of Medicine,  
PhD studies in neurology 
Professional employment: 
2007–  Tartu University Hospital, Department of Neurology,  
clinical neurophysiologist 
Scientific work and professional organizations:  
Research fields: Epileptology, neurophysiology 
Publications: 7 international, 3 domestic 
Membership: Estonian Society of Neurologists and Neurosurgeons, Estonian 
League Against Epilepsy, Estonian Society of Clinical Neurophysiology, 
Estonian Headache Society 
List of publications: 
Jefremov V, Rakitin A, Mahlapuu R, Zilmer K, Bogdanovic N, Zilmer M, Karel-
son E. 17beta-Oestradiol stimulation of G-proteins in aged and Alzheimer’s 
human brain: comparison with phytoestrogens. J. Neuroendocrinol. 2008; 
20(5):587–596. 
Rakitin A, Liik M, Õun A, Haldre S. Mortality risk in adults with newly diag-
nosed and chronic epilepsy: a population-based study. Eur. J. Neurol. 2011; 
18(3):465–470. 
Rakitin A, Eglit T, Kõks S, Lember M, Haldre S. Comparison of the metabolic 
syndrome risk in valproate-treated patients with epilepsy and the general 
population in Estonia. PLoS One. 2014;9(7):e103856. 
Rakitin A, Kõks S, Reimann E, Prans E, Haldre S. Changes in the peripheral 
blood gene expression profile induced by 3 months of valproate treatment in 
patients with newly diagnosed epilepsy. Front. Neurol. 2015;6:188. 
Rakitin A, Kõks S, Haldre S. Valproate modulates glucose metabolism in patients 
with epilepsy after first exposure. Epilepsia. 2015;56(11):e172–175. 
Braschinsky M, Raidvee A, Sabre L, Zmachinskaja N, Zukovskaja O, Karask 
A, Saar B, Rakitin A. 3D cinema and headache: the first evidential relation 
and analysis of involved factors. Front. Neurol. 2016;7:30. 
Rakitin A, Kõks S, Haldre S. Metabolic syndrome and anticonvulsants: A com-
parative study of valproic acid and carbamazepine. Seizure 2016;38:11–16. 
ELULOOKIRJELDUS 
112
Nimi:  Aleksei Rakitin 
Sünniaeg:  2.09.1978, Tartu 
Kodakondsus:  Eesti 
Aadress:  Puusepa 8H, 51014, Tartu 
Telefon:  7318 8557 
E-post:  Aleksei.Rakitin@kliinikum.ee 
Hariduskäik: 
1985–1996  Tartu Annelinna Gümnaasium 
1997–2003  Tartu Ülikool, Arstiteaduskond, arstiteadus 
2003–2007  Tartu Ülikool, Arstiteaduskond, neuroloogia residentuur 
2010–  Tartu Ülikool, Arstiteaduskond, arstiteadus, doktoriõpe 
Teenistuskäik: 
2007–  SA TÜK Närvikliinik, neuroloogia osakond, kliiniline 
neurofüsioloog 
Teadus- ja erialane tegevus: 
Valdkonnad: Epilepsia, neurofüsioloogia 
Publikatsioonid: 7 rahvusvahelistes ja 3 kohalikes meditsiiniajakirjades 
Liikmelisus: L. Puusepa nim. Neuroloogide ja Neurokirurgide selts, Eesti 
Epilepsiavastane Liiga, Eesti Kliinilise Neurofüsioloogia Selts, Eesti Peavalu 
Selts 
Publikatsioonid: 
Jefremov V, Rakitin A, Mahlapuu R, Zilmer K, Bogdanovic N, Zilmer M, Karel-
son E. 17beta-Oestradiol stimulation of G-proteins in aged and Alzheimer’s 
human brain: comparison with phytoestrogens. J. Neuroendocrinol. 2008; 
20(5):587–596. 
Rakitin A, Liik M, Õun A, Haldre S. Mortality risk in adults with newly diag-
nosed and chronic epilepsy: a population-based study. Eur. J. Neurol. 2011; 
18(3):465–470. 
Rakitin A, Eglit T, Kõks S, Lember M, Haldre S. Comparison of the metabolic 
syndrome risk in valproate-treated patients with epilepsy and the general 
population in Estonia. PLoS One. 2014;9(7):e103856. 
Rakitin A, Kõks S, Reimann E, Prans E, Haldre S. Changes in the peripheral 
blood gene expression profile induced by 3 months of valproate treatment in 
patients with newly diagnosed epilepsy. Front. Neurol. 2015;6:188. 
Rakitin A, Kõks S, Haldre S. Valproate modulates glucose metabolism in pa-
tients with epilepsy after first exposure. Epilepsia. 2015;56(11):e172–175. 
Braschinsky M, Raidvee A, Sabre L, Zmachinskaja N, Zukovskaja O, Karask A, 
Saar B, Rakitin A. 3D cinema and headache: the first evidential relation and 
analysis of involved factors. Front. Neurol. 2016;7:30. 
Rakitin A, Kõks S, Haldre S. Metabolic syndrome and anticonvulsants: A com-
parative study of valproic acid and carbamazepine. Seizure 2016;38:11–16. 
113 
DISSERTATIONES MEDICINAE  
UNIVERSITATIS TARTUENSIS 
 
 1. Heidi-Ingrid Maaroos. The natural course of gastric ulcer in connection 
with chronic gastritis and Helicobacter pylori. Tartu, 1991. 
 2. Mihkel Zilmer. Na-pump in normal and tumorous brain tissues: Structu-
ral, functional and tumorigenesis aspects. Tartu, 1991. 
 3. Eero Vasar. Role of cholecystokinin receptors in the regulation of beha-
viour and in the action of haloperidol and diazepam. Tartu, 1992. 
 4. Tiina Talvik. Hypoxic-ischaemic brain damage in neonates (clinical, 
biochemical and brain computed tomographical investigation). Tartu, 1992. 
 5. Ants Peetsalu. Vagotomy in duodenal ulcer disease: A study of gastric 
acidity, serum pepsinogen I, gastric mucosal histology and Helicobacter 
pylori. Tartu, 1992. 
 6. Marika Mikelsaar. Evaluation of the gastrointestinal microbial ecosystem 
in health and disease. Tartu, 1992. 
 7. Hele Everaus. Immuno-hormonal interactions in chronic lymphocytic leu-
kaemia and multiple myeloma. Tartu, 1993. 
 8. Ruth Mikelsaar. Etiological factors of diseases in genetically consulted 
children and newborn screening: dissertation for the commencement of the 
degree of doctor of medical sciences. Tartu, 1993. 
 9. Agu Tamm. On metabolic action of intestinal microflora: clinical aspects. 
Tartu, 1993. 
 10. Katrin Gross. Multiple sclerosis in South-Estonia (epidemiological and 
computed tomographical investigations). Tartu, 1993. 
 11. Oivi Uibo. Childhood coeliac disease in Estonia: occurrence, screening, 
diagnosis and clinical characterization. Tartu, 1994. 
 12. Viiu Tuulik. The functional disorders of central nervous system of che-
mistry workers. Tartu, 1994. 
 13. Margus Viigimaa. Primary haemostasis, antiaggregative and anticoagulant 
treatment of acute myocardial infarction. Tartu, 1994. 
 14. Rein Kolk. Atrial versus ventricular pacing in patients with sick sinus 
syndrome. Tartu, 1994. 
 15. Toomas Podar. Incidence of childhood onset type 1 diabetes mellitus in 
Estonia. Tartu, 1994. 
 16. Kiira Subi. The laboratory surveillance of the acute respiratory viral 
infections in Estonia. Tartu, 1995. 
17. Irja Lutsar. Infections of the central nervous system in children (epidemi-
ologic, diagnostic and therapeutic aspects, long term outcome). Tartu, 1995. 
18. Aavo Lang. The role of dopamine, 5-hydroxytryptamine, sigma and 
NMDA receptors in the action of antipsychotic drugs. Tartu, 1995. 
19.  Andrus Arak. Factors influencing the survival of patients after radical 
surgery for gastric cancer. Tartu, 1996. 
114
20.  Tõnis Karki. Quantitative composition of the human lactoflora and 
method for its examination. Tartu, 1996. 
21. Reet Mändar. Vaginal microflora during pregnancy and its transmission 
to newborn. Tartu, 1996.  
22. Triin Remmel. Primary biliary cirrhosis in Estonia: epidemiology, clinical 
characterization and prognostication of the course of the disease. Tartu, 
1996. 
23. Toomas Kivastik. Mechanisms of drug addiction: focus on positive rein-
forcing properties of morphine. Tartu, 1996.  
24.  Paavo Pokk. Stress due to sleep deprivation: focus on GABAA receptor-
chloride ionophore complex. Tartu, 1996. 
25. Kristina Allikmets. Renin system activity in essential hypertension. As-
sociations with atherothrombogenic cardiovascular risk factors and with 
the efficacy of calcium antagonist treatment. Tartu, 1996. 
26. Triin Parik. Oxidative stress in essential hypertension: Associations with 
metabolic disturbances and the effects of calcium antagonist treatment. 
Tartu, 1996. 
27.  Svetlana Päi. Factors promoting heterogeneity of the course of rheumatoid 
arthritis. Tartu, 1997.  
28. Maarike Sallo. Studies on habitual physical activity and aerobic fitness in 
4 to 10 years old children. Tartu, 1997. 
29. Paul Naaber. Clostridium difficile infection and intestinal microbial eco-
logy. Tartu, 1997. 
30. Rein Pähkla. Studies in pinoline pharmacology. Tartu, 1997. 
31. Andrus Juhan Voitk. Outpatient laparoscopic cholecystectomy. Tartu, 1997. 
32. Joel Starkopf. Oxidative stress and ischaemia-reperfusion of the heart. 
Tartu, 1997. 
33.  Janika Kõrv. Incidence, case-fatality and outcome of stroke. Tartu, 1998. 
34. Ülla Linnamägi. Changes in local cerebral blood flow and lipid peroxida-
tion following lead exposure in experiment. Tartu, 1998. 
35. Ave Minajeva. Sarcoplasmic reticulum function: comparison of atrial and 
ventricular myocardium. Tartu, 1998. 
36. Oleg Milenin. Reconstruction of cervical part of esophagus by revascular-
ised ileal autografts in dogs. A new complex multistage method. Tartu, 
1998. 
37. Sergei Pakriev. Prevalence of depression, harmful use of alcohol and 
alcohol dependence among rural population in Udmurtia. Tartu, 1998. 
38. Allen Kaasik. Thyroid hormone control over β-adrenergic signalling 
system in rat atria. Tartu, 1998. 
39. Vallo Matto. Pharmacological studies on anxiogenic and antiaggressive 
properties of antidepressants. Tartu, 1998. 
40. Maire Vasar. Allergic diseases and bronchial hyperreactivity in Estonian 
children in relation to environmental influences. Tartu, 1998. 
41. Kaja Julge. Humoral immune responses to allergens in early childhood. 
Tartu, 1998. 
115
42. Heli Grünberg. The cardiovascular risk of Estonian schoolchildren. 
A cross-sectional study of 9-, 12- and 15-year-old children. Tartu, 1998. 
43. Epp Sepp. Formation of intestinal microbial ecosystem in children. Tartu, 
1998. 
44. Mai Ots. Characteristics of the progression of human and experimental 
glomerulopathies. Tartu, 1998. 
45. Tiina Ristimäe. Heart rate variability in patients with coronary artery 
disease. Tartu, 1998. 
46. Leho Kõiv. Reaction of the sympatho-adrenal and hypothalamo-pituitary-
adrenocortical system in the acute stage of head injury. Tartu, 1998. 
47. Bela Adojaan. Immune and genetic factors of childhood onset IDDM in 
Estonia. An epidemiological study. Tartu, 1999. 
48. Jakov Shlik. Psychophysiological effects of cholecystokinin in humans. 
Tartu, 1999. 
49. Kai Kisand. Autoantibodies against dehydrogenases of α-ketoacids. Tartu, 
1999. 
50. Toomas Marandi. Drug treatment of depression in Estonia. Tartu, 1999. 
51. Ants Kask. Behavioural studies on neuropeptide Y. Tartu, 1999. 
52. Ello-Rahel Karelson. Modulation of adenylate cyclase activity in the rat 
hippocampus by neuropeptide galanin and its chimeric analogs. Tartu, 1999. 
53. Tanel Laisaar. Treatment of pleural empyema — special reference to 
intrapleural therapy with streptokinase and surgical treatment modalities. 
Tartu, 1999. 
54. Eve Pihl. Cardiovascular risk factors in middle-aged former athletes. 
Tartu, 1999. 
55.  Katrin Õunap. Phenylketonuria in Estonia: incidence, newborn screening, 
diagnosis, clinical characterization and genotype/phenotype correlation. 
Tartu, 1999. 
56. Siiri Kõljalg. Acinetobacter – an important nosocomial pathogen. Tartu, 
1999. 
57. Helle Karro. Reproductive health and pregnancy outcome in Estonia: 
association with different factors. Tartu, 1999. 
58. Heili Varendi. Behavioral effects observed in human newborns during 
exposure to naturally occurring odors. Tartu, 1999.  
59. Anneli Beilmann. Epidemiology of epilepsy in children and adolescents in 
Estonia. Prevalence, incidence, and clinical characteristics. Tartu, 1999. 
60. Vallo Volke. Pharmacological and biochemical studies on nitric oxide in 
the regulation of behaviour. Tartu, 1999. 
61.  Pilvi Ilves. Hypoxic-ischaemic encephalopathy in asphyxiated term infants. 
A prospective clinical, biochemical, ultrasonographical study. Tartu, 1999. 
62. Anti Kalda. Oxygen-glucose deprivation-induced neuronal death and its 
pharmacological prevention in cerebellar granule cells. Tartu, 1999. 
63.  Eve-Irene Lepist. Oral peptide prodrugs – studies on stability and 
absorption. Tartu, 2000. 
116
64. Jana Kivastik. Lung function in Estonian schoolchildren: relationship 
with anthropometric indices and respiratory symptomas, reference values 
for dynamic spirometry. Tartu, 2000. 
65. Karin Kull. Inflammatory bowel disease: an immunogenetic study. Tartu, 
2000. 
66. Kaire Innos. Epidemiological resources in Estonia: data sources, their 
quality and feasibility of cohort studies. Tartu, 2000. 
67. Tamara Vorobjova. Immune response to Helicobacter pylori and its 
association with dynamics of chronic gastritis and epithelial cell turnover 
in antrum and corpus. Tartu, 2001. 
68. Ruth Kalda. Structure and outcome of family practice quality in the 
changing health care system of Estonia. Tartu, 2001. 
69. Annika Krüüner. Mycobacterium tuberculosis – spread and drug 
resistance in Estonia. Tartu, 2001. 
70. Marlit Veldi. Obstructive Sleep Apnoea: Computerized Endopharyngeal 
Myotonometry of the Soft Palate and Lingual Musculature. Tartu, 2001. 
71. Anneli Uusküla. Epidemiology of sexually transmitted diseases in Estonia 
in 1990–2000. Tartu, 2001. 
72. Ade Kallas. Characterization of antibodies to coagulation factor VIII. 
Tartu, 2002. 
73. Heidi Annuk. Selection of medicinal plants and intestinal lactobacilli as 
antimicrobil components for functional foods. Tartu, 2002.  
74. Aet Lukmann. Early rehabilitation of patients with ischaemic heart 
disease after surgical revascularization of the myocardium:  assessment of 
health-related quality of life, cardiopulmonary reserve and oxidative stress. 
A clinical study. Tartu, 2002. 
75. Maigi Eisen. Pathogenesis of Contact Dermatitis: participation of Oxida-
tive Stress. A clinical – biochemical study. Tartu, 2002. 
76. Piret Hussar. Histology of the post-traumatic bone repair in rats. Elabora-
tion and use of a new standardized experimental model – bicortical perfora-
tion of tibia compared to internal fracture and resection osteotomy. Tartu, 
2002. 
77. Tõnu Rätsep. Aneurysmal subarachnoid haemorrhage: Noninvasive moni-
toring of cerebral haemodynamics. Tartu, 2002. 
78. Marju Herodes. Quality of life of people with epilepsy in Estonia. Tartu, 
2003. 
79. Katre Maasalu. Changes in bone quality due to age and genetic disorders 
and their clinical expressions in Estonia. Tartu, 2003. 
80. Toomas Sillakivi. Perforated peptic ulcer in Estonia: epidemiology, risk 
factors and relations with Helicobacter pylori. Tartu, 2003. 
81. Leena Puksa. Late responses in motor nerve conduction studies. F and A 
waves in normal subjects and patients with neuropathies. Tartu, 2003. 
82. Krista Lõivukene. Helicobacter pylori in gastric microbial ecology and  
its antimicrobial susceptibility pattern. Tartu, 2003. 
117
83. Helgi Kolk. Dyspepsia and Helicobacter pylori infection: the diagnostic 
value of symptoms, treatment and follow-up of patients referred for upper 
gastrointestinal endoscopy by family physicians. Tartu, 2003. 
84. Helena Soomer. Validation of identification and age estimation methods 
in forensic odontology. Tartu, 2003. 
85. Kersti Oselin. Studies on the human MDR1, MRP1, and MRP2 ABC 
transporters: functional relevance of the genetic polymorphisms in the 
MDR1 and MRP1 gene. Tartu, 2003. 
86. Jaan Soplepmann. Peptic ulcer haemorrhage in Estonia: epidemiology, 
prognostic factors, treatment and outcome. Tartu, 2003. 
87. Margot Peetsalu. Long-term follow-up after vagotomy in duodenal ulcer 
disease: recurrent ulcer, changes in the function, morphology and Helico-
bacter pylori colonisation of the gastric mucosa. Tartu, 2003. 
88. Kersti Klaamas. Humoral immune response to Helicobacter pylori a study 
of host-dependent and microbial factors. Tartu, 2003. 
89. Pille Taba. Epidemiology of Parkinson’s disease in Tartu, Estonia. Pre-
valence, incidence, clinical characteristics, and pharmacoepidemiology. 
Tartu, 2003.  
90. Alar Veraksitš. Characterization of behavioural and biochemical pheno-
type of cholecystokinin-2 receptor deficient mice: changes in the function 
of the dopamine and endopioidergic system. Tartu, 2003. 
91. Ingrid Kalev. CC-chemokine receptor 5 (CCR5) gene polymorphism in 
Estonians and in patients with Type I and Type II diabetes mellitus. Tartu, 
2003. 
92. Lumme Kadaja. Molecular approach to the regulation of mitochondrial 
function in oxidative muscle cells. Tartu, 2003. 
93. Aive Liigant. Epidemiology of primary central nervous system tumours in 
Estonia from 1986 to 1996. Clinical characteristics, incidence, survival and 
prognostic factors. Tartu, 2004. 
94. Andres, Kulla. Molecular characteristics of mesenchymal stroma in 
human astrocytic gliomas. Tartu, 2004. 
95. Mari Järvelaid. Health damaging risk behaviours in adolescence. Tartu, 
2004. 
96. Ülle Pechter. Progression prevention strategies in chronic renal failure and 
hypertension. An experimental and clinical study. Tartu, 2004. 
97. Gunnar Tasa. Polymorphic glutathione S-transferases – biology and role 
in modifying genetic susceptibility to senile cataract and primary open 
angle glaucoma. Tartu, 2004. 
98. Tuuli Käämbre. Intracellular energetic unit: structural and functional 
aspects. Tartu, 2004. 
99.  Vitali Vassiljev. Influence of nitric oxide syntase inhibitors on the effects  
of ethanol after acute and chronic ethanol administration and withdrawal. 
Tartu, 2004. 
118 
100. Aune Rehema. Assessment of nonhaem ferrous iron and glutathione 
redox ratio as markers of pathogeneticity of oxidative stress in different 
clinical groups. Tartu, 2004. 
101.   Evelin Seppet. Interaction of mitochondria and ATPases in oxidative 
muscle cells in normal and pathological conditions. Tartu, 2004. 
102. Eduard Maron. Serotonin function in panic disorder: from clinical expe-
riments to brain imaging and genetics. Tartu, 2004.  
103. Marje Oona. Helicobacter pylori infection in children: epidemiological 
and therapeutic aspects. Tartu, 2004. 
104. Kersti Kokk. Regulation of active and passive molecular transport in the 
testis. Tartu, 2005.  
105. Vladimir Järv. Cross-sectional imaging for pretreatment evaluation and 
follow-up of pelvic malignant tumours. Tartu, 2005. 
106. Andre Õun. Epidemiology of adult epilepsy in Tartu, Estonia. Incidence, 
prevalence and medical treatment. Tartu, 2005. 
107. Piibe Muda. Homocysteine and hypertension: associations between 
homocysteine and essential hypertension in treated and untreated hyper-
tensive patients with and without coronary artery disease. Tartu, 2005. 
108. Külli Kingo. The interleukin-10 family cytokines gene polymorphisms in 
plaque psoriasis. Tartu, 2005.  
109. Mati Merila. Anatomy and clinical relevance of the glenohumeral joint  
capsule and ligaments. Tartu, 2005. 
110. Epp Songisepp. Evaluation of technological and functional properties of 
the new probiotic Lactobacillus fermentum ME-3. Tartu, 2005. 
111. Tiia Ainla. Acute myocardial infarction in Estonia: clinical characte-
ristics, management and outcome. Tartu, 2005. 
112. Andres Sell. Determining the minimum local anaesthetic requirements for 
hip replacement surgery under spinal anaesthesia – a study employing a 
spinal catheter. Tartu, 2005. 
113. Tiia Tamme. Epidemiology of odontogenic tumours in Estonia. Patho-
genesis and clinical behaviour of ameloblastoma. Tartu, 2005. 
114. Triine Annus. Allergy in Estonian schoolchildren: time trends and 
characteristics. Tartu, 2005. 
115. Tiia Voor. Microorganisms in infancy and development of allergy: com-
parison  of  Estonian  and Swedish  children. Tartu, 2005. 
116. Priit Kasenõmm. Indicators for tonsillectomy in adults with recurrent 
tonsillitis – clinical, microbiological and pathomorphological investi-
gations. Tartu, 2005. 
117. Eva Zusinaite. Hepatitis C virus: genotype identification and interactions 
between viral proteases. Tartu, 2005. 
118. Piret Kõll. Oral lactoflora in chronic periodontitis and periodontal health. 
Tartu, 2006. 
119. Tiina Stelmach. Epidemiology of cerebral palsy and unfavourable neuro-
developmental outcome in child population of Tartu city and county, 
Estonia Prevalence, clinical features and risk factors. Tartu, 2006. 
119
120. Katrin Pudersell. Tropane alkaloid production and riboflavine excretion 
in the field and tissue cultures of henbane (Hyoscyamus niger L.). Tartu, 
2006.  
121. Külli Jaako. Studies on the role of neurogenesis in brain plasticity. Tartu, 
2006.  
122. Aare Märtson. Lower limb lengthening: experimental studies of bone 
regeneration and long-term clinical results. Tartu, 2006. 
123.  Heli Tähepõld. Patient consultation in family medicine. Tartu, 2006. 
124. Stanislav Liskmann. Peri-implant disease: pathogenesis, diagnosis and 
treatment in view of both inflammation and oxidative stress profiling. 
Tartu, 2006. 
125. Ruth Rudissaar. Neuropharmacology of atypical antipsychotics and an 
animal model of psychosis. Tartu, 2006. 
126. Helena Andreson. Diversity of Helicobacter pylori genotypes in 
Estonian patients with chronic inflammatory gastric diseases. Tartu, 2006. 
127. Katrin Pruus. Mechanism of action of antidepressants: aspects of sero-
toninergic system and its interaction with glutamate. Tartu, 2006. 
128. Priit Põder. Clinical and experimental investigation: relationship of 
ischaemia/reperfusion injury with oxidative stress in abdominal aortic 
aneurysm repair and in extracranial brain artery endarterectomy and possi-
bilities of protection against ischaemia using a glutathione analogue in a 
rat model of global brain ischaemia. Tartu, 2006.   
129. Marika Tammaru. Patient-reported outcome measurement in rheumatoid 
arthritis. Tartu, 2006. 
130.   Tiia Reimand. Down syndrome in Estonia. Tartu, 2006. 
131. Diva Eensoo. Risk-taking in traffic and Markers of Risk-Taking Beha-
viour in Schoolchildren and Car Drivers. Tartu, 2007. 
132. Riina Vibo. The third stroke registry in Tartu, Estonia from 2001 to 2003: 
incidence, case-fatality, risk factors and long-term outcome. Tartu, 2007.  
133. Chris Pruunsild. Juvenile idiopathic arthritis in children in Estonia. 
Tartu, 2007. 
134. Eve Õiglane-Šlik. Angelman and Prader-Willi syndromes in Estonia. 
Tartu, 2007. 
135. Kadri Haller. Antibodies to follicle stimulating hormone. Significance in 
female infertility. Tartu, 2007. 
136.  Pille Ööpik. Management of depression in family medicine. Tartu, 2007. 
137. Jaak Kals. Endothelial function and arterial stiffness in patients with 
atherosclerosis and in healthy subjects. Tartu, 2007. 
138.  Priit Kampus. Impact of inflammation, oxidative stress and age on 
arterial stiffness and carotid artery intima-media thickness. Tartu, 2007. 
139.  Margus Punab. Male fertility and its risk factors in Estonia. Tartu, 2007. 
140. Alar Toom. Heterotopic ossification after total hip arthroplasty: clinical 
and pathogenetic investigation. Tartu, 2007. 
120
141. Lea Pehme. Epidemiology of tuberculosis in Estonia 1991–2003 with 
special regard to extrapulmonary tuberculosis and delay in diagnosis of 
pulmonary tuberculosis. Tartu, 2007. 
142.  Juri Karjagin. The pharmacokinetics of metronidazole and meropenem 
in septic shock. Tartu, 2007. 
143. Inga Talvik. Inflicted traumatic brain injury shaken baby syndrome in 
Estonia – epidemiology and outcome. Tartu, 2007. 
144.  Tarvo Rajasalu. Autoimmune diabetes: an immunological study of type 
1 diabetes in humans and in a model of experimental diabetes (in RIP-
B7.1 mice). Tartu, 2007. 
145. Inga Karu. Ischaemia-reperfusion injury of the heart during coronary 
surgery: a clinical study investigating the effect of hyperoxia. Tartu, 2007. 
146. Peeter Padrik. Renal cell carcinoma: Changes in natural history and 
treatment of metastatic disease. Tartu, 2007.  
147.  Neve Vendt. Iron deficiency and iron deficiency anaemia in infants aged 
9 to 12 months in Estonia. Tartu, 2008.  
148. Lenne-Triin Heidmets. The effects of neurotoxins on brain plasticity: 
focus on neural Cell Adhesion Molecule. Tartu, 2008. 
149.  Paul Korrovits. Asymptomatic inflammatory prostatitis: prevalence, etio-
logical factors, diagnostic tools. Tartu, 2008. 
150.   Annika Reintam. Gastrointestinal failure in intensive care patients. Tartu, 
2008. 
151.   Kristiina Roots. Cationic regulation of Na-pump in the normal, Alzhei-
mer’s and CCK2 receptor-deficient brain. Tartu, 2008. 
152. Helen Puusepp. The genetic causes of mental retardation in Estonia: 
fragile X syndrome and creatine transporter defect. Tartu, 2009. 
153. Kristiina Rull. Human chorionic gonadotropin beta genes and recurrent 
miscarriage: expression and variation study. Tartu, 2009. 
154.  Margus Eimre. Organization of energy transfer and feedback regulation 
in oxidative muscle cells. Tartu, 2009. 
155. Maire Link. Transcription factors FoxP3 and AIRE: autoantibody 
associations. Tartu, 2009. 
156.  Kai Haldre. Sexual health and behaviour of young women in Estonia. 
Tartu, 2009. 
157. Kaur Liivak. Classical form of congenital adrenal hyperplasia due to  
21-hydroxylase deficiency in Estonia: incidence, genotype and phenotype 
with special attention to short-term growth and 24-hour blood pressure. 
Tartu, 2009. 
158. Kersti Ehrlich. Antioxidative glutathione analogues (UPF peptides) – 
molecular design, structure-activity relationships and testing the protec-
tive properties. Tartu, 2009. 
159. Anneli Rätsep. Type 2 diabetes care in family medicine. Tartu, 2009. 
160. Silver Türk. Etiopathogenetic aspects of chronic prostatitis: role of 
mycoplasmas, coryneform bacteria and oxidative stress. Tartu, 2009. 
121 
161. Kaire Heilman. Risk markers for cardiovascular disease and low bone 
mineral density in children with type 1 diabetes. Tartu, 2009. 
162.  Kristi Rüütel. HIV-epidemic in Estonia: injecting drug use and quality of 
life of people living with HIV. Tartu, 2009. 
163. Triin Eller. Immune markers in major depression and in antidepressive 
treatment. Tartu, 2009. 
164.  Siim Suutre. The role of TGF-β isoforms and osteoprogenitor cells in the 
pathogenesis of heterotopic ossification. An experimental and clinical 
study of hip arthroplasty. Tartu, 2010. 
165.  Kai Kliiman. Highly drug-resistant tuberculosis in Estonia: Risk factors 
and predictors of poor treatment outcome. Tartu, 2010.  
166.  Inga Villa. Cardiovascular health-related nutrition, physical activity and 
fitness in Estonia. Tartu, 2010. 
167. Tõnis Org. Molecular function of the first PHD finger domain of Auto-
immune Regulator protein. Tartu, 2010.  
168. Tuuli Metsvaht. Optimal antibacterial therapy of neonates at risk of early 
onset sepsis. Tartu, 2010. 
169.  Jaanus Kahu. Kidney transplantation: Studies on donor risk factors and 
mycophenolate mofetil. Tartu, 2010.  
170.  Koit Reimand. Autoimmunity in reproductive failure: A study on as-
sociated autoantibodies and autoantigens. Tartu, 2010. 
171. Mart Kull. Impact of vitamin D and hypolactasia on bone mineral 
density: a population based study in Estonia. Tartu, 2010. 
172. Rael Laugesaar. Stroke in children – epidemiology and risk factors. 
Tartu, 2010.  
173.  Mark Braschinsky. Epidemiology and quality of life issues of hereditary 
spastic paraplegia in Estonia and implemention of genetic analysis in 
everyday neurologic practice. Tartu, 2010. 
174. Kadri Suija. Major depression in family medicine: associated factors, 
recurrence and possible intervention. Tartu, 2010. 
175. Jarno Habicht. Health care utilisation in Estonia: socioeconomic determi-
nants and financial burden of out-of-pocket payments. Tartu, 2010. 
176. Kristi Abram. The prevalence and risk factors of rosacea. Subjective 
disease perception of rosacea patients. Tartu, 2010. 
177. Malle Kuum. Mitochondrial and endoplasmic reticulum cation fluxes: 
Novel roles in cellular physiology. Tartu, 2010. 
178. Rita Teek. The genetic causes of early onset hearing loss in Estonian 
children. Tartu, 2010. 
179. Daisy Volmer. The development of community pharmacy services in 
Estonia – public and professional perceptions 1993–2006. Tartu, 2010. 
180. Jelena Lissitsina. Cytogenetic causes in male infertility. Tartu, 2011. 
181.  Delia Lepik. Comparison of gunshot injuries caused from Tokarev, 
Makarov and Glock 19 pistols at different firing distances. Tartu, 2011. 
182.  Ene-Renate Pähkla. Factors related to the efficiency of treatment of 
advanced periodontitis. Tartu, 2011.  
122
183. Maarja Krass. L-Arginine pathways and antidepressant action. Tartu, 
2011.  
184.  Taavi Lai. Population health measures to support evidence-based  
health policy in Estonia. Tartu, 2011.  
185. Tiit Salum. Similarity and difference of temperature-dependence of the 
brain sodium pump in normal, different neuropathological, and aberrant 
conditions and its possible reasons. Tartu, 2011.  
186.  Tõnu Vooder. Molecular differences and similarities between histo-
logical subtypes of non-small cell lung cancer. Tartu, 2011.  
187.  Jelena Štšepetova. The characterisation of intestinal lactic acid bacteria 
using bacteriological, biochemical and molecular approaches. Tartu, 2011.  
188. Radko Avi. Natural polymorphisms and transmitted drug resistance in 
Estonian HIV-1 CRF06_cpx and its recombinant viruses. Tartu, 2011, 116 p. 
189.  Edward Laane. Multiparameter flow cytometry in haematological malig-
nancies. Tartu, 2011, 152 p. 
190.  Triin Jagomägi. A study of the genetic etiology of nonsyndromic cleft lip 
and palate. Tartu, 2011, 158 p. 
191.  Ivo Laidmäe. Fibrin glue of fish (Salmo salar) origin: immunological 
study and development of new pharmaceutical preparation. Tartu, 2012, 
150 p. 
192.  Ülle Parm. Early mucosal colonisation and its role in prediction of inva-
sive infection in neonates at risk of early onset sepsis. Tartu, 2012, 168 p. 
193.  Kaupo Teesalu. Autoantibodies against desmin and transglutaminase 2 in 
celiac disease: diagnostic and functional significance. Tartu, 2012, 142 p. 
194. Maksim Zagura. Biochemical, functional and structural profiling of 
arterial damage in atherosclerosis. Tartu, 2012, 162 p. 
195. Vivian Kont. Autoimmune regulator: characterization of thymic gene 
regulation and promoter methylation. Tartu, 2012, 134 p. 
196. Pirje Hütt. Functional properties, persistence, safety and efficacy of 
potential probiotic lactobacilli. Tartu, 2012, 246 p. 
197.  Innar Tõru. Serotonergic modulation of CCK-4- induced panic. Tartu, 
2012, 132 p. 
198.  Sigrid Vorobjov. Drug use, related risk behaviour and harm reduction 
interventions utilization among injecting drug users in Estonia: impli-
cations for drug policy. Tartu, 2012, 120 p. 
199.  Martin Serg. Therapeutic aspects of central haemodynamics, arterial 
stiffness and oxidative stress in hypertension. Tartu, 2012, 156 p.  
200. Jaanika Kumm. Molecular markers of articular tissues in early knee 
osteoarthritis: a population-based longitudinal study in middle-aged sub-
jects. Tartu, 2012, 159 p. 
201. Kertu Rünkorg. Functional changes of dopamine, endopioid and endo-
cannabinoid systems in CCK2 receptor deficient mice. Tartu, 2012, 125 p. 
202. Mai Blöndal. Changes in the baseline characteristics, management and 
outcomes of acute myocardial infarction in Estonia. Tartu, 2012, 127 p.        
123 
203. Jana Lass. Epidemiological and clinical aspects of medicines use in 
children in Estonia. Tartu, 2012, 170 p. 
204. Kai Truusalu. Probiotic lactobacilli in experimental persistent Salmo-
nella infection. Tartu, 2013, 139 p.  
205. Oksana Jagur.  Temporomandibular joint diagnostic imaging in relation 
to pain and bone characteristics. Long-term results of arthroscopic treat-
ment. Tartu, 2013, 126 p. 
206. Katrin Sikk. Manganese-ephedrone intoxication – pathogenesis of neuro-
logical damage and clinical symptomatology. Tartu, 2013, 125 p. 
207. Kai Blöndal. Tuberculosis in Estonia with special emphasis on drug-
resistant tuberculosis: Notification rate, disease recurrence and mortality. 
Tartu, 2013, 151 p. 
208. Marju Puurand. Oxidative phosphorylation in different diseases of 
gastric mucosa. Tartu, 2013, 123 p.  
209. Aili Tagoma. Immune activation in female infertility: Significance of 
autoantibodies and inflammatory mediators. Tartu, 2013, 135 p. 
210.  Liis Sabre. Epidemiology of traumatic spinal cord injury in Estonia. 
Brain activation in the acute phase of traumatic spinal cord injury. Tartu, 
2013, 135 p. 
211. Merit Lamp. Genetic susceptibility factors in endometriosis. Tartu, 2013, 
125 p. 
212.  Erik Salum. Beneficial effects of vitamin D and angiotensin II receptor 
blocker on arterial damage. Tartu, 2013, 167 p.   
213.  Maire Karelson. Vitiligo: clinical aspects, quality of life and the role of 
melanocortin system in pathogenesis. Tartu, 2013, 153 p.  
214. Kuldar Kaljurand. Prevalence of exfoliation syndrome in Estonia and its 
clinical significance. Tartu, 2013, 113 p.  
215.  Raido Paasma. Clinical study of methanol poisoning: handling large out-
breaks, treatment with antidotes, and long-term outcomes. Tartu, 2013,  
96 p. 
216.  Anne Kleinberg. Major depression in Estonia: prevalence, associated 
factors, and use of health services. Tartu, 2013, 129 p. 
217.  Triin Eglit. Obesity, impaired glucose regulation, metabolic syndrome 
and their associations with high-molecular-weight adiponectin levels. 
Tartu, 2014, 115 p. 
218.  Kristo Ausmees. Reproductive function in middle-aged males: Asso-
ciations with prostate, lifestyle and couple infertility status. Tartu, 2014, 
125 p.  
219.  Kristi Huik. The influence of host genetic factors on the susceptibility to 
HIV and HCV infections among intravenous drug users. Tartu, 2014, 
144 p.  
220. Liina Tserel. Epigenetic profiles of monocytes, monocyte-derived macro-
phages and dendritic cells. Tartu, 2014, 143 p. 
221. Irina Kerna. The contribution of ADAM12 and CILP genes to the 
development of knee osteoarthritis. Tartu, 2014, 152 p. 
124
222. Ingrit Liiv. Autoimmune regulator protein interaction with DNA-depen-
dent protein kinase and its role in apoptosis. Tartu, 2014, 143 p. 
223.  Liivi Maddison. Tissue perfusion and metabolism during intra-abdominal 
hypertension. Tartu, 2014, 103 p. 
224.  Krista Ress. Childhood coeliac disease in Estonia, prevalence in atopic 
dermatitis and immunological characterisation of coexistence. Tartu, 
2014, 124 p. 
225.  Kai Muru. Prenatal screening strategies, long-term outcome of children 
with marked changes in maternal screening tests and the most common 
syndromic heart anomalies in Estonia. Tartu, 2014, 189 p. 
226. Kaja Rahu. Morbidity and mortality among Baltic Chernobyl cleanup 
workers: a register-based cohort study. Tartu, 2014, 155 p.  
227.  Klari Noormets. The development of diabetes mellitus, fertility and ener-
gy metabolism disturbances in a Wfs1-deficient mouse model of Wolfram 
syndrome. Tartu, 2014, 132 p. 
228. Liis Toome. Very low gestational age infants in Estonia. Tartu, 2014,  
183 p. 
229.  Ceith Nikkolo. Impact of different mesh parameters on chronic pain and 
foreign body feeling after open inguinal hernia repair. Tartu, 2014, 132 p. 
230.  Vadim Brjalin. Chronic hepatitis C: predictors of treatment response in 
Estonian patients. Tartu, 2014, 122 p. 
231.  Vahur Metsna. Anterior knee pain in patients following total knee arthro-
plasty: the prevalence, correlation with patellar cartilage impairment and 
aspects of patellofemoral congruence. Tartu, 2014, 130 p. 
232.  Marju Kase. Glioblastoma multiforme: possibilities to improve treatment 
efficacy. Tartu, 2015, 137 p.  
233. Riina Runnel. Oral health among elementary school children and the 
effects of polyol candies on the prevention of dental caries. Tartu, 2015, 
112 p. 
234. Made Laanpere. Factors influencing women’s sexual health and re-
productive choices in Estonia. Tartu, 2015, 176 p. 
235.  Andres Lust. Water mediated solid state transformations of a polymorphic 
drug – effect on pharmaceutical product performance. Tartu, 2015, 134 p.  
236. Anna Klugman. Functionality related characterization of pretreated wood 
lignin, cellulose and polyvinylpyrrolidone for pharmaceutical applications. 
Tartu, 2015, 156 p. 
237. Triin Laisk-Podar. Genetic variation as a modulator of susceptibility to 
female infertility and a source for potential biomarkers. Tartu, 2015, 155 p. 
238. Mailis Tõnisson. Clinical picture and biochemical changes in blood in 
children with acute alcohol intoxication. Tartu, 2015, 100 p. 
239. Kadri Tamme. High volume haemodiafiltration in treatment of severe 
sepsis – impact on pharmacokinetics of antibiotics and inflammatory 




240. Kai Part. Sexual health of young people in Estonia in a social context: the 
role of school-based sexuality education and youth-friendly counseling 
services. Tartu, 2015, 203 p. 
241. Urve Paaver. New perspectives for the amorphization and physical 
stabilization of poorly water-soluble drugs and understanding their 
dissolution behavior. Tartu, 2015, 139 p. 
242. Aleksandr Peet. Intrauterine and postnatal growth in children with HLA-
conferred susceptibility to type 1 diabetes. Tartu. 2015, 146 p. 
243. Piret Mitt. Healthcare-associated infections in Estonia – epidemiology 
and surveillance of bloodstream and surgical site infections. Tartu, 2015, 
145 p. 
244.  Merli Saare. Molecular Profiling of Endometriotic Lesions and Endo-
metria of Endometriosis Patients. Tartu, 2016, 129 p. 
245.  Kaja-Triin Laisaar. People living with HIV in Estonia: Engagement in 
medical care and methods of increasing adherence to antiretroviral therapy 
and safe sexual behavior. Tartu, 2016, 132 p. 
246. Eero Merilind. Primary health care performance: impact of payment and 
practice-based characteristics. Tartu, 2016, 120 p. 
247. Jaanika Kärner. Cytokine-specific autoantibodies in AIRE deficiency. 
Tartu, 2016, 182 p. 
248. Kaido Paapstel. Metabolomic profile of arterial stiffness and early 
biomarkers of renal damage in atherosclerosis. Tartu, 2016, 173 p. 
249.  Liidia Kiisk. Long-term nutritional study: anthropometrical and clinico-
laboratory assessments in renal replacement therapy patients after 
intensive nutritional counselling. Tartu, 2016, 207 p. 
250. Georgi Nellis. The use of excipients in medicines administered to neo-
nates in Europe. Tartu, 2017, 159 p. 
